Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
A beta-lactamase preferentially cleaving penicillins. (Dorland, 28th ed) EC 3.5.2.-.
Cyclic AMIDES formed from aminocarboxylic acids by the elimination of water. Lactims are the enol forms of lactams.
A cyclohexylamido analog of PENICILLANIC ACID.
Substances that reduce the growth or reproduction of BACTERIA.
A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain.
A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.
A publication issued at stated, more or less regular, intervals.
"The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.
The premier bibliographic database of the NATIONAL LIBRARY OF MEDICINE. MEDLINE® (MEDLARS Online) is the primary subset of PUBMED and can be searched on NLM's Web site in PubMed or the NLM Gateway. MEDLINE references are indexed with MEDICAL SUBJECT HEADINGS (MeSH).
Publications in any medium issued in successive parts bearing numerical or chronological designations and intended to be continued indefinitely. (ALA Glossary of Library and Information Science, 1983, p203)
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
Databases containing information about PROTEINS such as AMINO ACID SEQUENCE; PROTEIN CONFORMATION; and other properties.
A process that includes the determination of AMINO ACID SEQUENCE of a protein (or peptide, oligopeptide or peptide fragment) and the information analysis of the sequence.
The procedures involved in combining separately developed modules, components, or subsystems so that they work together as a complete system. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
The protein complement of an organism coded for by its genome.
Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein.
Facilities equipped to carry out investigative procedures.
Methods, procedures, and tests performed to diagnose disease, disordered function, or disability.
Materials incorporated mechanically in plastics (usually PVC) to increase flexibility, workability or distensibility; due to the non-chemical inclusion, plasticizers leach out from the plastic and are found in body fluids and the general environment.
The science and technology dealing with the procurement, breeding, care, health, and selection of animals used in biomedical research and testing.
A family of gram-negative, facultatively anaerobic, rod-shaped bacteria that do not form endospores. Its organisms are distributed worldwide with some being saprophytes and others being plant and animal parasites. Many species are of considerable economic importance due to their pathogenic effects on agriculture and livestock.
Infections with bacteria of the family ENTEROBACTERIACEAE.
Nonsusceptibility of bacteria to the action of the beta-lactam antibiotics. Mechanisms responsible for beta-lactam resistance may be degradation of antibiotics by BETA-LACTAMASES, failure of antibiotics to penetrate, or low-affinity binding of antibiotics to targets.
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc.
Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).
Proteins obtained from ESCHERICHIA COLI.
Beverages consumed as stimulants and tonics. They usually contain a combination of CAFFEINE with other substances such as herbal supplements; VITAMINS; AMINO ACIDS; and sugar or sugar derivatives.
The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Infections with bacteria of the species ESCHERICHIA COLI.
Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures.
A genus of gram-negative, rod-shaped enterobacteria that can use citrate as the sole source of carbon.
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria found in humans and other animals including MAMMALS; BIRDS; REPTILES; and AMPHIBIANS. It has also been isolated from SOIL and WATER as well as from clinical specimens such as URINE; THROAT; SPUTUM; BLOOD; and wound swabs as an opportunistic pathogen.
A species of gram-negative enterobacteria found in WATER; SEWAGE; SOIL; and FOOD. It can be present in any clinical specimen as an opportunistic pathogen.
A species of gram-negative bacteria in the genus CITROBACTER, family ENTEROBACTERIACEAE. As an important pathogen of laboratory mice, it serves as a model for investigating epithelial hyperproliferation and tumor promotion. It was previously considered a strain of CITROBACTER FREUNDII.
A strain of the VIBRIO CHOLERAE bacteria belonging to serogroup non-O1, infecting humans and other PRIMATES. It is related to VIBRIO CHOLERAE O1, but causes a disease less severe than CHOLERA. Eating raw shellfish contaminated with the bacteria results in GASTROENTERITIS.
The etiologic agent of CHOLERA.
An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.
Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.
Strains of VIBRIO CHOLERAE containing O ANTIGENS group 139. This strain emerged in India in 1992 and caused a CHOLERA epidemic.
Inorganic salts or organic esters of phosphorous acid that contain the (3-)PO3 radical. (From Grant & Hackh's Chemical Dictionary, 5th ed)
Temporary visual deficit or impaired visual processing occurring in a rapid serial visual presentation task. After a person identifies the first of two visual targets, the ability to detect the second target is impaired for the next few hundred milliseconds. This phenomenon is called attentional blink.
Time period from 1901 through 2000 of the common era.
The practice of compounding and dispensing medicinal preparations.
Four-membered cyclic AMIDES, best known for the PENICILLINS based on a bicyclo-thiazolidine, as well as the CEPHALOSPORINS based on a bicyclo-thiazine, and including monocyclic MONOBACTAMS. The BETA-LACTAMASES hydrolyze the beta lactam ring, accounting for BETA-LACTAM RESISTANCE of infective bacteria.

pKa calculations for class A beta-lactamases: influence of substrate binding. (1/5548)

Beta-Lactamases are responsible for bacterial resistance to beta-lactams and are thus of major clinical importance. However, the identity of the general base involved in their mechanism of action is still unclear. Two candidate residues, Glu166 and Lys73, have been proposed to fulfill this role. Previous studies support the proposal that Glu166 acts during the deacylation, but there is no consensus on the possible role of this residue in the acylation step. Recent experimental data and theoretical considerations indicate that Lys73 is protonated in the free beta-lactamases, showing that this residue is unlikely to act as a proton abstractor. On the other hand, it has been proposed that the pKa of Lys73 would be dramatically reduced upon substrate binding and would thus be able to act as a base. To check this hypothesis, we performed continuum electrostatic calculations for five wild-type and three beta-lactamase mutants to estimate the pKa of Lys73 in the presence of substrates, both in the Henri-Michaelis complex and in the tetrahedral intermediate. In all cases, the pKa of Lys73 was computed to be above 10, showing that it is unlikely to act as a proton abstractor, even when a beta-lactam substrate is bound in the enzyme active site. The pKa of Lys234 is also raised in the tetrahedral intermediate, thus confirming a probable role of this residue in the stabilization of the tetrahedral intermediate. The influence of the beta-lactam carboxylate on the pKa values of the active-site lysines is also discussed.  (+info)

Structure-function studies of Ser-289 in the class C beta-lactamase from Enterobacter cloacae P99. (2/5548)

Site-directed mutagenesis of Ser-289 of the class C beta-lactamase from Enterobacter cloacae P99 was performed to investigate the role of this residue in beta-lactam hydrolysis. This amino acid lies near the active site of the enzyme, where it can interact with the C-3 substituent of cephalosporins. Kinetic analysis of six mutant beta-lactamases with five cephalosporins showed that Ser-289 can be substituted by amino acids with nonpolar or polar uncharged side chains without altering the catalytic efficiency of the enzyme. These data suggest that Ser-289 is not essential in the binding or hydrolytic mechanism of AmpC beta-lactamase. However, replacement by Lys or Arg decreased by two- to threefold the kcat of four of the five beta-lactams tested, particularly cefoperazone, cephaloridine, and cephalothin. Three-dimensional models of the mutant beta-lactamases revealed that the length and positive charge of the side chain of Lys and Arg could create an electrostatic linkage to the C-4 carboxylic acid group of the dihydrothiazine ring of the acyl intermediate which could slow the deacylation step or hinder release of the product.  (+info)

Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum beta-lactamase encoded by an Escherichia coli integron gene. (3/5548)

A clinical isolate, Escherichia coli MG-1, isolated from a 4-month-old Vietnamese orphan child, produced a beta-lactamase conferring resistance to extended-spectrum cephalosporins and aztreonam. In a disk diffusion test, a typical synergistic effect between ceftazidime or aztreonam and clavulanic acid was observed along with an unusual synergy between cefoxitin and cefuroxime. The gene for VEB-1 (Vietnamese extended-spectrum beta-lactamase) was cloned and expressed in E. coli JM109. The recombinant plasmid pRLT1 produced a beta-lactamase with a pI of 5.35 and conferred high-level resistance to extended-spectrum (or oxyimino) cephalosporins and to aztreonam. Vmax values for extended-spectrum cephalosporins were uncommonly high, while the affinity of the enzyme for ceftazidime and aztreonam was relatively low. blaVEB-1 showed significant homology at the DNA level with only blaPER-1 and blaPER-2. Analysis of the deduced protein sequence showed that VEB-1 is a class A penicillinase having very low levels of homology with any other known beta-lactamases. The highest percentage of amino acid identity was 38% with PER-1 or PER-2, two uncommon class A extended-spectrum enzymes. Exploration of the genetic environment of blaVEB-1 revealed the presence of gene cassette features, i.e., (i) a 59-base element associated with blaVEB-1; (ii) a second 59-base element just upstream of blaVEB-1, likely belonging to the aacA1-orfG gene cassette; (iii) two core sites (GTTRRRY) on both sides of blaVEB-1; and (iv) a second antibiotic resistance gene 3' of blaVEB-1, aadB. blaVEB-1 may therefore be the first class A extended-spectrum beta-lactamase that is part of a gene cassette, which itself is likely to be located on a class 1 integron, as sulfamide resistance may indicate. Furthermore, blaVEB-1 is encoded on a large (> 100-kb) transferable plasmid found in a Klebsiella pneumoniae MG-2 isolated at the same time from the same patient, indicating a horizontal gene transfer.  (+info)

Use of an isogenic Escherichia coli panel to design tests for discrimination of beta-lactamase functional groups of Enterobacteriaceae. (4/5548)

A study was designed to determine if an isogenic panel of Escherichia coli strains containing many different beta-lactamases could be used for the preliminary screening of a large number of beta-lactam agents to identify which might be most useful in the development of a definitive test for specific beta-lactamases found among the members of family Enterobacteriaceae. The susceptibilities of 46 strains, comprising the isogenic panel, to expanded-spectrum cephalosporins, cephamycins, and aztreonam were determined in the presence and absence of beta-lactamase inhibitors in broth microdilution tests. The results indicated that strains producing extended-spectrum beta-lactamases (ESBLs) could be distinguished from strains producing other Bush-Jacoby-Medeiros functional group 2 or group 1 beta-lactamases. For strains producing group 1 beta-lactamases, cefpodoxime and ceftazidime MICs were > or = 4 micrograms/ml and addition of clavulanate did not reduce the MICs more than fourfold. For strains producing group 2 enzymes other than ESBLs, cefpodoxime and ceftazidime MICs were < or = 2 micrograms/ml. With a single exception (ceftazidime for the strain producing SHV-3), among strains producing ESBLs, cefpodoxime and ceftazidime MICs were > or = 4 micrograms/ml and addition of clavulanate reduced the MICs by more than eightfold. Cephamycins could also be used to discriminate between strains producing group 1 beta-lactamases and ESBLs, since only the former required cefotetan concentrations as high as 8 micrograms/ml or cefoxitin concentrations of > 16 micrograms/ml for inhibition. Other cephalosporins provided some discrimination between the various beta-lactamase producers, although they were not as reliable as either cefpodoxime or ceftazidime. These results indicate the utility of an isogenic panel for identification of candidate drugs among many for further testing with clinical isolates of the family Enterobacteriaceae to determine the best agents for detection of specific beta-lactamases in this family.  (+info)

Ketolide treatment of Haemophilus influenzae experimental pneumonia. (5/5548)

The MICs of HMR 3004 and HMR 3647 at which 90% of beta-lactamase-producing Haemophilus influenzae isolates were inhibited were 4 and 2 micrograms/ml, respectively. Both HMR 3004 and HMR 3647 were active against beta-lactamase-producing H. influenzae in a murine model of experimental pneumonia. As assessed by pulmonary clearance of H. influenzae, HMR 3004 was more effective (P < 0.05) than was azithromycin, ciprofloxacin, clarithromycin, erythromycin A, pristinamycin, or HMR 3647 in this model.  (+info)

Mechanisms of beta-lactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey. (6/5548)

The mechanisms of resistance to beta-lactam antibiotics in 325 isolates of Pseudomonas aeruginosa were examined. These isolates were selected because of their resistance to meropenem and imipenem (breakpoint, >4 mg/L), carbenicillin (>128 mg/L), ceftazidime (>8 mg/L), piperacillin and ticarcillin/clavulanate (>64 mg/L). The most frequent mechanism of resistance was beta-lactamase-independent, so called 'intrinsic resistance', which was found in 183 isolates and was probably due to impermeability and/or efflux mechanisms. beta-Lactamase-mediated resistance was demonstrated in 111 strains (11.1%). Derepression of Ambler Class C chromosomal beta-lactamase was detected in 64 isolates, most of which were resistant to ceftazidime and piperacillin but susceptible to meropenem, whereas secondary plasmid-encoded beta-lactamases were found in 34 isolates, all of them resistant to carboxypenicillins and ureidopenicillins and susceptible to carbapenems. Twelve strains showed more than one plasmid-encoded beta-lactamase plus derepression of chromosomal Class C enzyme. Resistance to carbapenems was independent of resistance to other beta-lactam antibiotics, indicating a different mechanism of resistance, probably due to the loss of the D2 porin. In total, 32 strains were resistant to carbapenems: 24 only to imipenem and eight to both imipenem and meropenem.  (+info)

Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid and ethambutol. (7/5548)

Thirty clinical isolates of Mycobacterium tuberculosis, 20 of which were multidrug-resistant (MDR), were tested for susceptibility to different combinations of amoxycillin, clavulanic acid and subinhibitory concentrations of ethambutol. beta-Lactamase production was assessed semiquantitatively with the nitrocefin method and susceptibility testing was performed with the BACTEC method. All isolates were beta-lactamase positive and were resistant to 16 mg/L amoxycillin. The MIC of amoxycillin in combination with clavulanic acid was > or =2 mg/L for 27/30 (90%) isolates. Addition of subinhibitory concentrations of ethambutol significantly reduced the MIC of amoxycillin for all tested isolates. Twenty-nine (97%) isolates had an MIC of amoxycillin of < or =0.5 mg/L when subinhibitory concentrations of ethambutol were added; this is well below the concentrations achievable in serum and tissue.  (+info)

Resistance of artificial biofilms of Pseudomonas aeruginosa to imipenem and tobramycin. (8/5548)

Viable cells of Pseudomonas aeruginosa were entrapped in alginate gel layers and incubated in a minimal glucose (15 g/L)-yeast extract (2 g/L)-salt medium to form artificial biofilm-like structures. After cultivation for 2 days, the biomass distribution inside the polymer was highly heterogeneous. The cell number reached approximately 1011 cells/g gel in the outer regions of the gel structures whereas the inner areas were less colonized (c. 10(8) cells g/gel). Killing of immobilized organisms by imipenem and tobramycin were compared with free-cell experiments (inoculum c. 10(9) cells/mL). Sessile-like bacteria displayed a higher resistance to the two antibiotics used alone or in combination than did suspended cells. Exposure for 10 h to 20 x MIC imipenem and 15 x MIC tobramycin reduced the number of viable immobilized bacteria to 0.3% and 3%, respectively, of the initial cell population, whereas these antibiotic concentrations were much more efficient (bactericidal) against free-cell cultures (5 log kill in 6 h). A synergic effect of tobramycin and imipenem was detected on bacterial suspensions but not on biofilm-like structures. Effective diffusivity measurements showed that the diffusion of imipenem in the alginate layer was not hindered. A slight but significant enhancement of beta-lactamase induction in immobilized cells as compared with their suspended counterparts was insufficient to explain the high resistance of sessile-like bacteria.  (+info)

Background: Escherichia coli is the most common causative agent of urinary tract infection. Antibiotic resistance among uropathogens has become a prominent public health problem. Multidrug resistance bacteria have limited the therapeutic possibilities by producing Extended Spectrum Beta Lactamases (ESBL). Objective: Since routine monitoring of ESBL producers are not conducted in clinical laboratories their true prevalence is still unknown. So the objective of this research was to assess multiple antibiotic resistance (MAR) indices and determine ESBL production among Escherichia coli isolated from urine samples. Methods: Standard microbiological techniques and antibiotic sensitivity test were performed by Kirby Bauer disc diffusion method to identify E. coli. ESBL screening was done by using Ceftriaxone, Aztreonam, Cefotaxime, Ceftazidime and Cefpodoxime whereas confirmation by combined disc assay. SPSS 16 software was used to analyze data. Results: 86.95% E. coli isolates were MDR strains. 27 ...
Free Online Library: TEM & SHV genes in extended spectrum [beta]-lactamase producing Klebsiella species & their antimicrobial resistance pattern.(Temoneira, Sulphydryl variable, Report) by Indian Journal of Medical Research; Health, general Biological sciences Beta lactamases Genetic aspects Physiological aspects Drug resistance in microorganisms Genes Microbial drug resistance
Introduction: Community acquired urinary tract infections (CA-UTI) are commonly caused by Escherichia coli and Klebsiella spp which are known extended spectrum beta lactamase (ESBL) producers.. Objectives: To determine, the prevalence and characteristics of ESBL producing of E. coli and Klebsiella spp in the community, and the association of risk factors with ESBL CA-UTI.. Methods: Descriptive cross-sectional study with urine cultures performed from clinically suspected CA-UTI patients by CLSI standards. Conventional multiplex PCR was performed for gene analysis.. Results: Cultures were positive in 178 (38%) patients from 465. Majority were females (103, 58%). Most frequently isolated was E. coli (149, 84%) with 68(46%) ESBL producers followed by 16(9%) Klebsiella pneumoniae with 4 (25%) ESBL producers. Majority of patients with ESBL CA-UTI were ,50 yrs (35/72, 49%) and 13 (18%) children ,10 years were present. ABST of ESBL producers revealed high resistance rates for quinolones (41%) and ,80% ...
Production of AmpC and extended spectrum beta-lactamases among urinary isolates has created a serious problem to the successful management of the urinary tract infection. The main purpose of this study was to determine the rates of the extended spectrum beta-lactamase (ESBL) production and AmpC beta-lactamase (ABL) production among urinary isolates. Among total 564 urinary isolates, 514 (91.1%) were gram negative bacilli and 50 (8.9%) were gram positive cocci. E. coli (76.1%) was the most common bacteria isolated. Staphylococcus aureus (6.7%) was the predominant gram positive bacteria isolated. 35 (6.8%) of the 514 gram negative bacilli were ESBL producers. Similarly, 14 (2.7%) of the gram negative bacilli were ABL producers. Only one isolate was ESBL and ABL co-producer. Highest rate of susceptibility of gram negative bacteria was seen toward amikacin (97.3%) followed by imipenem (94.4%). Similarly, highest rate of susceptibility among gram positive cocci was seen toward vancomycin (100%) followed by
Sixty isolates of Enterobacteriaceae resistant to beta-lactam antibiotics were collected over a period of 2 years in Switzerland and screened by hybridization for the carriage of SHV genes. Thirty-four positive strains were found, and their SHV genes were amplified and sequenced. SHV extended-spectrum beta-lactamases (ESBLs) were found: 13 strains contained SHV-2a, 12 harbored SHV-2, and SHV-5 was found twice. Four strains were shown to contain SHV-1. In addition, we report two new SHV variants, termed SHV-11 (non-ESBL) and SHV-12 (ESBL). In spite of the carriage of SHV ESBLs, many strains showed only low resistance to one or more third-generation cephalosporins. In addition, 26 did not transfer the blaSHV gene in mating experiments. ...
A new extended-spectrum beta-lactamase was detected in a lactose-positive Salmonella enterica subsp. enterica strain that caused a nosocomial outbreak involving eight patients in a pediatric cardiology unit. This strain showed high levels of resistance to ceftazidime and aztreonam and relatively low levels of resistance to cefotaxime and ceftriaxone. Resistance was associated with a conjugative plasmid of 59 kb, which encoded a new beta-lactamase with an isoelectric point of 5.9 that strongly hydrolyzed ceftazidime and to a much lesser extent hydrolyzed cefotaxime. The enzyme activity was inhibited by clavulanate. The corresponding bla gene was cloned and sequenced. The deduced amino acid sequence showed three significant amino acid replacements with respect to the TEM-1 sequence: Arg-164--,His, Glu-240--,Lys, and Thr-265--,Met. This combination is unique among extended-spectrum beta-lactamases and served to characterize the new enzyme, TEM-27. ...
Read Faecal colonization of E. coli and Klebsiella spp. producing extended-spectrum beta-lactamases and plasmid-mediated AmpC in Mozambican university students, BMC Infectious Diseases on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
Gram-negative bacteria such as Escherichia coli or Klebsiella spp. frequently cause bloodstream infections. There has been a worldwide increase in resistance in these species to antibiotics such as third generation cephalosporins, largely driven by the acquisition of extended-spectrum beta-lactamase or plasmid-mediated AmpC enzymes. Carbapenems have been considered the most effective therapy for serious infections caused by such resistant bacteria; however, increased use creates selection pressure for carbapenem resistance, an emerging threat arising predominantly from the dissemination of genes encoding carbapenemases. Recent retrospective data suggest that beta-lactam/beta-lactamase inhibitor combinations, such as piperacillin-tazobactam, may be non-inferior to carbapenems for the treatment of bloodstream infection caused by extended-spectrum beta-lactamase-producers, if susceptible in vitro. This study aims to test this hypothesis in an effort to define carbapenem-sparing alternatives for these
Mono- and Stereopictres of 5.0 Angstrom coordination sphere of Cobalt atom in PDB 1fof: Crystal Structure of the Class D Beta-Lactamase Oxa-10
The ICD10 code for the diagnosis Extended spectrum beta lactamase (ESBL) resistance is Z16.12. Z16.12 is a VALID/BILLABLE ICD10 code, i.e it is valid for submission for HIPAA-covered transactions.
Background and Objectives: Pseudomonas aeruginosa is an important pathogen in clinical infections, which has different mechanisms of antibiotic resistance. Extended spectrum β lactamases (ESBLs) are a very important mechanism of antibiotic resistance in this bacterium. The objective of this study was to determine the prevalence of CTX-M gene in ESBL-producing P. ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Purpose. The objective of the present study was to evaluate the prevalence of intestinal colonization with extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) and carbapenemase-producing Enterobacteriaceae (CPE) in non-selected hospitalized and non-hospitalized patients from the same geographic area of Madrid. Methodology. A total of 501 fecal samples were screened. Diluted samples in saline were cultured in MacConkey agar plates with ceftazidime, cefotaxime, imipenem and meropenem disks. Colonies growing within the inhibition zone of either disk were selected. Characterization of ESBLs and CPEs were performed by PCR and sequencing. The Wider system was used for the bacterial identification. In addition, clonal analysis was carried out for species predominant among the fecal carriage. Key Findings. Among the 501 patients enrolled, 43 (8.6 %) carried ESBL-E and 8 (1.6 %) patients exhibited CPE. The main intestinal colonizer among ESBL-E was CTX-M-producing Escherichia coli
Recently, extended spectrum beta lactamase (ESBL)-producing E. coli with a new genotype (blaCTX-M-1) emerged in the Norwegian broiler production pyramid. Occurrence of ESBL-producing bacteria such as E. coli is a global concern because they resist highly important antimicrobials known as third-generation cephalosporins used in human medicine. Development of ESBL-producing bacteria have resulted from the use and misuse of antimicrobials in humans and livestock production. However, Norway hardly use antimicrobials in its broiler production but still detected ESBL-producing E. coli with blaCTX-M-1. Thus, the goal of this study was to examine three questions regarding ESBL-producing E. coli emergence in the Norwegian broiler production pyramid. First, was this emergence a clonal spread of a specific ESBL-E. coli variant with one plasmid? Second, could it have been the clonal spread of several genetically unrelated E. coli variants with different plasmids and third, did a horizontal transfer of ...
Background & Aims: The production of extended-spectrum-β-lactamases (ESBLs) is the main mechanism of resistance to β-lactam antibiotics. The outbreak of isolates simultaneously possessing several resistance mechanisms to β-lactam antibiotics caused a decrease in sensitivity of the confirmatory tests for ESBL. The aim of this study was the evaluation of the β-lactamase disk test method in the detection of ESBLs in clinical isolates of multidrug-resistant Pseudomonas aeruginosa. Methods: A total of 100 multidrug-resistant P. aeruginosa isolates were recovered from burn patients. The sensitivity of the isolates to different antibiotics was determined using the standard disk diffusion method. ESBL-producing isolates were detected through the combination disk test with clavulanic acid, double disk synergy test, and β-lactamase disk test. Carbapenemase-producing isolates were detected using the Modified Hodge Test (MHT). The ESBLs genes (blaTEM, blaOXA, blaPER, blaSHV, blaCTX-M and blaPSE) were
In the United States, Klebsiella pneumoniae carbapenemase (KPC) is the most common carbapenemase, followed by New Delhi metallo-beta-lactamase (NDM). OXA-48-like and VIM carbapenemases predominate in other parts of the globe, but do occur in the United States. The genes blaOXA-48-like and blaVIM encode OXA-48-like and VIM enzyme production, respectively. PCR is a sensitive, specific, and rapid means of identifying these genes.. This test detects the genes encoding OXA-48-like (oxacillin-hydrolyzing beta-lactamase) and VIM (Verona integron-encoded metallo-beta-lactamase) types of beta-lactamases in stool and perirectal/rectal/perianal/anal swabs. It can be used as a tool to find colonized patients. The Centers for Disease Control and Prevention recommends surveillance to detect unrecognized colonized patients who may be a potential source for transmission of carbapenemase-producing Gram-negative bacilli under certain circumstances. Such surveillance may be focused in certain high-risk settings or ...
Two different strains of Escherichia coli exhibiting unusual patterns of resistance to beta-lactam antibiotics were isolated from patients at Cochin Hospital. Both isolates showed a low level of resistance to amoxycillin, ticarcillin and ureidopenicillins but were susceptible to cephalosporins, aztreonam and imipenem; beta-lactamase inhibitors potentiated the activities of the beta-lactams to only a limited extent. All resistance characteristics of the strains were transferable by conjugation to E. coli K12. Resistance was shown to be due to beta-lactamases of pI 5.20 and relative molecular masses of 24,000. The hydrolytic and inhibition profiles of these enzymes were similar to each other but differed from those of broad-spectrum beta-lactamases (TEM-1). The rates of hydrolysis (Vmax) of amoxycillin (c. 200%) were higher than that for TEM-1 (84%). Ticarcillin, ureidopenicillins and cephaloridine were hydrolyzed slowly. However, as for TEM-1, no hydrolysis was observed with cefoxitin, third generation
Archives issue of International Journal of Pharma and Bio Sciences which aims to cover the latest outstanding developments in the field of pharmaceutical and biological sciences
This study aims to isolate, to identify, and to seek out fragments of encoding gene Extended Spectrum β-Lactamase on Escherichia coli isolated from swab surface of broiler chicken meat in a number of traditional markets in Surabaya. The result shows that 31 out of 50 samples positively contain Escherichia coli, shown through EMBA isolation media and identified using indole test. Sensitivity test shows that 100% of the isolates are resistant to Ampicilin, 48.4% are resistant to Cephazoline, 13% are resistant to Ceftazidime, 9.6% are resistant to Cefotaxime, 6.4% are resistant to Ceftriaxone and 87.2% are resistant to Tetracycline. 8 out of 8 (100%) samples of E. coli resistant show the presence of band towards blaTEM gene of 768 basepair (bp).. ...
TY - JOUR. T1 - Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli. AU - Haruki, Yuto. AU - Hagiya, Hideharu. AU - Haruki, Mai. AU - Sugiyama, Tetsuhiro. PY - 2018/11. Y1 - 2018/11. N2 - The number of patients infected with extended-spectrum beta-lactamase (ESBL)-producing organisms has increased dramatically worldwide, and high mortality rates are seen in severely ill patients. This study retrospectively compared the clinical characteristics and outcomes of critically ill patients in an intensive care unit (ICU) at the Tsuyama Chuo Hospital (Okayama, Japan) who were hospitalized for bacteremia caused by ESBL-producing Escherichia coli (ESBL-EC) or non-ESBL-producing E. coli (non-ESBL-EC) between January 2006 and December 2016 (11 years). We analyzed the patients age, sex, underlying disease(s), sequential organ failure assessment scores, primary focus of bacteremia, empiric ...
TY - JOUR. T1 - The characteristics of metallo-β-lactamase-producing gram-negative bacilli isolated from sputum and urine. T2 - A single center experience in Korea. AU - Chin, Bum Sik. AU - Han, Sang Hoon. AU - Choi, Suk Hoon. AU - Lee, Han Sung. AU - Jeong, Su Jin. AU - Choi, Hee Kyung. AU - Choi, Jun Yong. AU - Song, Young Goo. AU - Kim, Chang Ki. AU - Yong, Dongeun. AU - Lee, Kyungwon. AU - Kim, June Myung. PY - 2011/3. Y1 - 2011/3. N2 - Metallo-β-lactamase (MBL) production usually results in high-level resistance to most β-lactams, and a rapid spread of MBL producing major gram-negative pathogens is a matter of particular concern worldwide. However, clinical data are scarce and most studies compared MBL producer (MP) with MBL non-producer (MNP) strains which included carbapenem susceptible isolates. Therefore, we collected clinical data of patients in whom imipenem-nonsusceptible Pseudomonas aeruginosa (PA) and Acinetobacter baumannii (AB) were isolated from sputum or urine, and ...
TY - JOUR. T1 - Extended-spectrum β-lactamases. AU - Patterson, Jan E.. PY - 2000/1/1. Y1 - 2000/1/1. N2 - Resistance to broad-spectrum cephalosporins among Klebsiella pneumoniae has increased significantly, particularly in the intensive care unit setting, in the past decade. The problem has been noted not only in the United States, but around the world. A major mechanism responsible for this is the emergence of extended-spectrum β-lactamases (ESBLs). These plasmid-mediated β-lactamases confer resistance to broad-spectrum β-lactam antibiotics, including third and fourth-generation cephalosporins, aztreonam, and extended-spectrum penicillins. Other resistances, such as aminoglycoside and trimethoprim-sulfamethoxazole resistance, are often cotransferred on the same plasmid. Fluoroquinolone resistance is also frequently associated, resulting in an organism resistant to most broad-spectrum options. The carbapenems are currently considered the drug of choice for these pathogens. Prevention and ...
Abstract: Susceptibility of nosocomial potential AmpC-beta-lactamases producers strains (n=128), isolated from patients admitted to 30 medical centers of 15 various regions of Russia has been investigated. The susceptibility testing was performed by the broth microdilution method. The most active antibacterial agents acting to the investigated strains remained carbapenems (imipenem and meropenem). PCR-based detection of beta-lactamase genes (TEM, SHV, CTX) was investigated in 51 E. cloacae strains. Alone or in various combinations TEM type beta-lactamases have been found in 31 (60,8%) isolates, SHV - in 22 (43,1%), and CTX - in 22 (43,1%). There were negative results of TEM, SHV, CTX beta-lactamases genotyping in 13 (25,5%) E. cloacae suspect strains ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Extended-spectrum beta lactamase-producing bacteria are one of the fastest emerging resistance problems worldwide. ESBL-producing bacteria were observed in human medical practice, the observation of these bacteria in companion animals and the increase in livestock has initiated monitoring studies concentrating on livestock [13, 21].. Livestock may be an important vehicle for the community-wide dissemination of antimicrobial-resistant Enterobacteriaceae, also P. aeruginosa especially ESBL-producing type isolates have been found in increasing numbers in food-producing animals [9, 10, 22].. Accordingly to the hypothesis that animals might become infection sources or even natural persistent sources acting as risky reservoirs of infection leading to the spread of these bacteria specifically multidrug resistant types in community [23]. There are essential needs for monitoring or surveillance studies incorporating veterinary medicine to identify transmissible pathogens to human and its risk ...
High prevalence of extended-spectrum β-lactamase-producing pathogens: results of a surveillance study in two hospitals in Ujjain, India Ashish Pathak1,2, Yogyata Marothi3, Vandana Kekre4, Kalpana Mahadik5, Ragini Macaden6, Cecilia Stålsby Lundborg11Division of Global Health, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden; 2Department of Pediatrics, 3Department of Microbiology, 4Department of Medicine, 5Department of Obstetrics and Gynecology, RD Gardi Medical College, Ujjain, India; 6St Johns Research Institute, Bangalore, IndiaBackground: Recent reports of the rapid evolution of bacterial resistance in India require urgent antibiotic stewardship programs. This study aimed to define the magnitude and pattern of resistance of bacterial pathogens to guide empirical therapy.Methods: We prospectively collected consecutive, clinically significant, and nonduplicate bacterial isolates from each patient from two hospitals in Ujjain, India. The antibiotic susceptibility
AmpC BER is an extended substrate spectrum class C beta-lactamase with a two-amino-acid insertion in the R2 loop compared with AmpC EC2. The crystal structures of AmpC BER (S64A mutant) and AmpC EC2 were determined. Structural comparison of the two proteins revealed that the insertion increases the conformational flexibility of the R2 loop. Two citrate molecules originating from the crystallization solution were observed in the active site of the S64A mutant. One citrate molecule makes extensive interactions with active-site residues that are highly conserved among class C beta-lactamases, whereas the other one is weakly bound. Based on this structural observation, it is demonstrated that citrate, a primary metabolite that is widely used as a food additive, is a competitive inhibitor of two class C beta-lactamases (AmpC BER and CMY-10). Consequently, the data indicate enhancement of the flexibility of the R2 loop as an operative strategy for molecular evolution of extended-spectrum class C ...
The number and proportion of CTX-M positive Escherichia coli organisms were determined in feces from cattle, chickens, and pigs in the United Kingdom to provide a better understanding of the risk of the dissemination of extended-spectrum β-lactamase (ESBL) bacteria to humans from food animal sources. Samples of bovine (n = 35) and swine (n = 20) feces were collected from farms, and chicken cecal contents (n = 32) were collected from abattoirs. There was wide variation in the number of CTX-M-positive E. coli organisms detected; the median (range) CFU/g were 100 (100 × 10(6) to 1 × 10(6)), 5,350 (100 × 10(6) to 3.1 × 10(6)), and 2,800 (100 × 10(5) to 4.7 × 10(5)) for cattle, chickens, and pigs, respectively. The percentages of E. coli isolates that were CTX-M positive also varied widely; median (range) values were 0.013% (0.001 to 1%) for cattle, 0.0197% (0.00001 to 28.18%) for chickens, and 0.121% (0.0002 to 5.88%) for pigs. The proportion of animals designated high-density shedders (≥1 ...
The present study evaluated the antimicrobial effect of different combinations of gentamicin and floroquinolones (ciprofloxacin, ofloxacin, perfloxacin and gatifloxacin) against extended spectrum beta lactamase (ESBL) positive E. coli isolates using checkerboard method. One hundred and four clinical isolates of E. coli obtained from urine (26), blood (24), stool (20), sputum (19) and semen (14) were investigated for ESBL production. Fifteen (14.4%) were positive for ESBL production in the following order: 4(3.8%) from urine, 3(2.8%) from blood, 3(2.8%) from stool, 3(2.8%) from sputum and 2(1.9%) from semen. Five representative ESBL positive isolates, one from each specimen, were investigated for their susceptibility patterns to different gentamicin and floroquinolone combinations. The combinations of gentamicin and ciprofloxacin, perfloxacin and gatifloxacin, respectively at different ratios were predominantly synergistic in activity while gentamicin and ofloxacin combinations were primarily ...
Antimicrobial Susceptibility-Extended Spectrum Beta Lactamase,ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories client,medicine,medical supply,medical supplies,medical product
CARB-9 beta-lactamases: a carbenicillinase encoded in the VCR region of Vibrio cholerae non-O1, non-O139 belongs to a family of cassette-encoded beta-lactamases
Beta-lactamases (β-lactamases, also known as penicillinase) are enzymes (EC 3.5.2.6) produced by bacteria, that provide multi-resistance to β-lactam antibiotics such as penicillins, cephalosporins, cephamycins, and carbapenems (ertapenem), although carbapenems are relatively resistant to beta-lactamase. Beta-lactamase provides antibiotic resistance by breaking the antibiotics structure. These antibiotics all have a common element in their molecular structure: a four-atom ring known as a β-lactam. Through hydrolysis, the lactamase enzyme breaks the β-lactam ring open, deactivating the molecules antibacterial properties. Beta-lactam antibiotics are typically used to treat a broad spectrum of Gram-positive and Gram-negative bacteria. Beta-lactamases produced by Gram-negative organisms are usually secreted, especially when antibiotics are present in the environment. The structure of a Streptomyces β-lactamase is given by 1BSG. Penicillinase is a specific type of β-lactamase, showing ...
Objectives: During 2003, the Health Protection Agencys Antibiotic Resistance Monitoring and Reference Laboratory began to receive isolates of Escherichia coli for confirmation of extended-spectrum β-lactamase production with a phenotype implying a CTX-M-type β-lactamase, i.e. MICs of cefotaxime ≥8-fold higher than MICs of ceftazidime. Many were referred as being from community patients. We examined 291 CTX-M-producing isolates from the UK and investigated the genetic basis of their phenotype.. Methods: PCR was used to detect alleles encoding CTX-M enzymes and to assign these to their blaCTX-M phylogenetic groups. Selected alleles were sequenced. Producers were compared by analysis of banding patterns generated by pulsed-field gel electrophoresis of XbaI-digested genomic DNA. MICs were determined by an agar dilution method or by Etest.. Results: Of 291 CTX-M-producing E. coli isolates studied from 42 UK centres, 70 (24%) were reportedly from community patients, many of whom had only limited ...
Learn more about Extended Spectrum Beta-Lactamase Infection at TriStar Centennial Parthenon Pavilion DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Extended-spectrum beta-lactamases (ESBLs), AmpC-type beta-lactamases (ACBLs) and carbapenemases are among the most important resistance mechanisms in Enterobacteriaceae. This study investigated the presence of these resistance mechanisms in consecutive non-replicate isolates of Escherichia coli (n = 2,352), Klebsiella pneumoniae (n = 697), and Proteus mirabilis (n = 275) from an Italian nationwide cross-sectional survey carried out in October 2013. Overall, 15.3% of isolates were non-susceptible to extended-spectrum cephalosporins but susceptible to carbapenems (ESCR-carbaS), while 4.3% were also non-susceptible to carbapenems (ESCR-carbaR). ESCR-carbaS isolates were contributed by all three species, with higher proportions among isolates from inpatients (20.3%) but remarkable proportions also among those from outpatients (11.1%). Most ESCR-carbaS isolates were ESBL-positive (90.5%), and most of them were contributed by E. coli carrying blaCTX-M group 1 genes. Acquired ACBLs were less common and mostly
Background and Objectives: Pathogenic bacteria, such as Escherichia coli are dangerous for human population due to acquisition of resistance genes to beta-lactam antibiotics. This resistance is due to extended spectrum β lactamase (ESBL) genes, which are caused by plasmids, transposons, and/or mutation. The main cause of resistance to beta-lactam antibiotics ...
Extended Spectrum Beta-Lactamases (ESBLs) encoding genes (TEM, SHV and OXA) were amplified from multidrug resistance E. coli. The multidrug resistance E. coli isolates from different clinical sources were documented to be plasmid encoded and resistance against β-lactam and cephalosporin. Conventional laboratory analysis showed that seventy percent (70%) of the selected multidrug resistant clinical isolates were ESBLs positive, showing a ≥5 mm increase in zone diameter for either antibiotics compared to its zone when tested alone. The antibiotic susceptibility result showed that 100% of the isolates were resistant to amoxicillin-clavulanic acid, amoxicillin, cefuroxime and ampicillin-sulbactam while 90% of the isolates were resistant to ceftazidine and tetracycline, 80% to ofloxacin, 70% to ceftriazon, nalidixic acid, cefalexin, 60% to ciprofloxacin, 50% to nitrofurantoin, 40% to chloramphenicol and 20% to gentamicine. The multiplex PCR with primers TEM (931bp), SHV (868), OXA-2 (478), aac(3)-IIa (900
Free Online Library: Community-acquired extended-spectrum [beta]-lactamase producers, United States.(LETTERS, Letter to the editor) by Emerging Infectious Diseases; Health, general Beta lactamases Health aspects Ciprofloxacin Infection
In the spring of 2010, it was discovered that a large proportion of broilers in Sweden were colonized with Escherichia coli producing extended-spectrum beta-lactamases (ESBL) or plasmid mediated AmpC (pAmpC). It was hypothesized that the high prevalence was due to transfer from an upper level in the production pyramid and sampling upwards in the production pyramid was initiated. From 2010 to 2019, all shipments (n = 122) of broiler breeders were screened on arrival to Sweden for the occurrence of ESBL- or pAmpC-producing E. coli using selective methods. Samples of paper linings from shipments of breeders were cultured on MacConkey agar supplemented with cefotaxime (1 mg/L) after pre-enrichment in either MacConkey broth with cefotaxime (1 mg/L), or from late June 2015 in buffered peptone water without antibiotics. ESBL- or pAmpC-producing E. coli was isolated from 43 (35%) of these. Over the years, the proportion of positive imports have decreased and during 2018 and 2019 all imports were negative. In
BioAssay record AID 43435 submitted by ChEMBL: Concentration required for its inhibitory activity against Escherichia coli K12(OXA1) class D beta-lactamase; Not tested.
Fazly Bazzaz, Bibi Sedigheh and Lavaei, Shokoufeh and Hosseinzadeh, Hossein (2012) Interaction of methylxanthines and gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa: Role of phosphodiesterase inhibition. Acta Microbiologica et Immunologica Hungarica, 59 (1). pp. 13-20. ISSN 1217-8950 Fazly Bazzaz, Bibi Sedigheh and Naderinasab, Mahboobeh and Mohamadpoor, Amir Hooshang and Farshadzadeh, Zahra and Ahmadi, Samaneh and Yousefi, Forough (2009) The prevalence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates from a general hospital in Iran. Acta Microbiologica et Immunologica Hungarica, 56 (1). pp. 89-99. ISSN 1217-8950 ...
Fazly Bazzaz, Bibi Sedigheh and Naderinasab, Mahboobeh and Mohamadpoor, Amir Hooshang and Farshadzadeh, Zahra and Ahmadi, Samaneh and Yousefi, Forough (2009) The prevalence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates from a general hospital in Iran. Acta Microbiologica et Immunologica Hungarica, 56 (1). pp. 89-99. ISSN 1217-8950 ...
Escherichia coli strains were isolated from a single dairy farm as a sentinel organism for the persistence of antibiotic resistance genes in the farm environment. Selective microbiological media were used to isolate 126 E. coli isolates from slurry and faeces samples from different farm areas. Antibiotic resistance profiling for 17 antibiotics (seven antibiotic classes), showed 57.9% of the isolates were resistant to between 3 and 15 antibiotics. The highest frequency of resistance was to ampicillin (56.3%), and the lowest to imipenem (1.6%), which appeared to be an unstable phenotype and was subsequently lost. Extended spectrum beta-lactamase resistance (ESBL) was detected in 53 isolates and blaCTX-M, blaTEM and blaOXA genes were detected by PCR in twelve, four and two strains, respectively. Phenotypically most isolates showing resistance to cephalosporins were AmpC rather than ESBL, a number of isolates having both activities. Phenotypic resistance patterns suggested co-acquisition of some ...
A 1536-nucleotide-long sequence that carries the ampC beta-lactamase gene of the Escherichia coli K-12 chromosome has been determined. This gene codes for a protein of 377 amino acids, of which the first 19 amino acids form a signal peptide. The molecular weight of the mature enzyme was determined to be 39,600. The ampC beta-lactamase with a substrate specificity for cephalosporins showed no significant sequence homologies with beta-lactamases of the penicillinase type or with D-alanine carboxypeptidases. However, because the region around serine-80 of the ampC beta-lactamase has extensive homology with an active-site fragment of the Pseudomonas aeruginosa cephalosporinase, we suggest that the ampC cephalosporinase as well as related cephalosporinases form a distinct group of serine beta-lactamases that have an evolutionary origin different from that of the serine penicillinases and thus constitute a new class of beta-lactamases.. ...
Anonymous, 2012: Biochemical and Genetic Characterization of Carbapenem-Hydrolyzing beta-Lactamase OXA-229 from Acinetobacter bereziniae
A total of 907 consecutive isolates of members of the family Enterobacteriaceae recovered during a 20-week period were tested for production of extended-spectrum beta-lactamases (ESBLs) by the double-disk (DD) potentiation method. Of 84 DD-positive isolates, 83 (9.2%) produced ESBLs based on isoelectric focusing. SHV-derived ESBLs and several TEM-derived ESBLs were present in nine species, including the first isolate of Citrobacter koserii and Morganella morganii known to harbor an SHV-derived ESBL. Results of testing 58 nonrepeat isolates for ESBL production by several recommended methods were as follows (percent detected in parentheses): DD method with aztreonam (95), ceftazidime (79), ceftriaxone (88), or cefpodoxime (90); broth microdilution method with ceftazidime (86) or cefotaxime (91) alone or in combination with clavulanate; and the standard disk diffusion method with new breakpoints and standard concentrations of aztreonam (78), ceftazidime (79), ceftriaxone (83), or cefpodoxime (98) ...
We report the very rare case of a huge appendical abscess with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E. coli) as the pathogen. There have been several reports of appendical infections such as appendicitis and appendical abscess caused by ESBL-producing bacteria in adults. The treatment of ESBL-producing E. coli infection is specific, and ESBL-producing bacteria have recently been reported as pathogens associated appendicitis in children. To the best of our knowledge, this is the second report of perforated appendicitis with abscess due to ESBL-producing E. coli. We discuss the diagnostic modalities and treatments for appendical abscess with ESBL-producing E. coli. and propose that the patients with perforated appendicitis and abscess formation due to ESBL-producing E. coli should be administered the antibiotic MEPM within 2 weeks to treat the abscess more effec-tively without producing other multidrug-resistant bacteria.
CTX-M extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae isolates are infrequently reported in the United States. In this study, we analyzed nonduplicate ESBL-producing K. pneumoniae and Escherichia coli clinical isolates collected during 2005-2012 at a tertiary care medical center in suburban New York City, USA, for the presence of blaCTX-M, blaSHV, blaTEM, and blaKPC genes. Despite a high prevalence of blaCTX-M genes in ESBL-producing E. coli since 2005, blaCTX-M genes were not detected in K. pneumoniae until 2009. The prevalence of CTX-M-producing K. pneumoniae increased significantly over time from 1.7% during 2005-2009 to 26.4% during 2010-2012 ( ...
Mora, A., Blanco, M., López, C., Mamani, R., Blanco, J.E., Alonso, M.P., García-Garrote, F., Dahbi, G. et al. (2011) Emergence of clonal groups O1:HNM-D-ST59, O15:H1-D-ST393, O20:H34/HNM-D-ST354, O25b:H4-B2-ST131 and ONT:H21,42-B1-ST101 among CTX-M-14-producing Escherichia coli clinical isolates in Galicia, northwest Spain. Int J Antimicrob Agents 37, 16-21 ...
The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β -lactamase in Enterobacter cloacae Christine Miossec, Monique Claudon, Premavathy Levasseur, Michael T Black Novexel, Romainville, France Abstract: Induction of ampC β-lactamase expression can often compromise antibiotic treatment and is triggered by several β-lactams (such as cefoxitin and imipenem) and by the β-lactamase inhibitor clavulanic acid. The novel β-lactamase inhibitor avibactam (NXL104) is a potent inhibitor of both class A and class C enzymes. The potential of avibactam for induction of ampC expression in Enterobacter cloacae was investigated by ampC messenger ribonucleic acid quantitation. Cefoxitin and clavulanic acid were confirmed as ampC inducers, whereas avibactam was found to exert no effect on ampC expression. Thus, avibactam is unlikely to diminish the activity of any partner β-lactam antibiotic against AmpC-producing organisms. Keywords: β-lactamase, ampC, induction, NXL104, avibactam
INFECTION CONTROL STAFF FACT SHEET Extended Spectrum Beta Lactamase (ESBL) producing organisms WHAT ARE THEY? • • • • • ESBLs (extended spectrum beta lactamases) are enzymes that may be produced by Gram negative bacteria. They were first reported in 1983. The bacteria have become resistant to beta-lactam antibiotics, by their ability to produce an enzyme (beta-lactamase) which can break down the antibiotics (eg. penicillins and cephalosporins). ESBL producing organisms not only have the ability to break down beta-lactam antibiotics but they are also able to transfer these resistance enzymes to other microorganisms via plasmids. The bacteria may also be resistant to other antibiotics such as aminoglycosides (eg. gentamycin and tobramycin) and quinolones (eg. ciprofloxacin). The most common ESBL producing organisms include Klebsiella spp, Enterobacter spp, Acinetobacter spp and Escherichia coli. HOW ARE THEY SPREAD? • • • ESBL producing organisms usually colonise the bowel without ...
The emergence of extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae represents a major challenge to public and animal health in many countries including Lebanon. Carriage of ESBLs confers resistance to β-lactam antibiotics and more than 200 different sub-types have been identified, all of which are primarily encoded by genes located on conjugative plasmids. Despite the high prevalence of ESBLs, there is still a paucity of information regarding the impact of ESBL plasmid carriage on the host bacterium and how the spread of antibiotic resistance relates to antibiotic use in hospital environments. Therefore, the aim of this study was, firstly, to characterise the genetic and phenotypic properties of ESBL-producing Escherichia coli and Klebsiella pneumoniae isolated from a hospital in Lebanon. Secondly, to assess the fitness of isolates harbouring different sub-types of ESBLs in order to better understand the influence of the plasmid on the host bacterium, and thirdly, to correlate ...
The emergence of multidrug-resistant (MDR) and extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae poses a serious antibiotic management problem as resistance genes are easily transferred from one organism to another. Fifty-one strains of K. pneumoniae isolated from sporadic cases in various hospitals throughout Malaysia were analysed by antimicrobial susceptibility testing, PCR detection of ESBL-encoding genes and DNA fingerprinting. Although 27 of the 51 K. pneumoniae strains were MDR (i.e. resistant to three or more classes of antibiotics), the majority of the strains (98 %) were sensitive to imipenem. PCR detection using ESBL gene-specific primers showed that 46 of the K. pneumoniae strains harboured bla SHV, 19 harboured bla CTX-M, 5 harboured bla OXA-1 and 4 harboured bla TEM-1. Class 1 integron-encoded intI1 integrase was detected in 21 of the 51 K. pneumoniae strains and amplification of the integron 5′CS region showed the presence of several known antibiotic resistance gene
IMP-type metallo-β-lactamase-producing bacteria have recently emerged worldwide. We conducted a case-control study in which 69 inpatients harboring blaIMP-positive Pseudomonas aeruginosa and 247 control subjects with blaIMP-negative pathogens were investigated. Prolonged hospitalization, antineoplastic chemotherapy, corticosteroid therapy (P =.001), and indwelling urinary catheters (P =.04) were risk factors for isolation of blaIMP-positive pathogens. The predominant source was urine (P =.001). The duration of antibiotic treatment and the total dose (including of carbapenems) were significantly greater among case patients than among control subjects (P ,.01). blaIMP-positive P. aeruginosa isolates were more frequently resistant to multiple drugs (P =.001) and caused more infections (P =.001) than blaIMP-negative pathogens. There were no significant differences in bacteriological outcome (P =.94); however, infection-related death was more frequent among case patients than among control subjects ...
Klebsiella oxytoca is primarily a health care-associated pathogen acquired from environmental sources. During October 2006-March 2011, a total of 66 patients in a hospital in Toronto, Ontario, Canada, acquired class A extended-spectrum β-lactamase-producing K. oxytoca with 1 of 2 related pulsed-field gel electrophoresis patterns. New cases continued to occur despite reinforcement of infection control practices, prevalence screening, and contact precautions for colonized/infected patients. Cultures from handwashing sinks in the intensive care unit yielded K. oxytoca with identical pulsed-field gel electrophoresis patterns to cultures from the clinical cases. No infections occurred after implementation of sink cleaning 3×/day, sink drain modifications, and an antimicrobial stewardship program. In contrast, a cluster of 4 patients infected with K. oxytoca in a geographically distant medical ward without contaminated sinks was contained with implementation of active screening and contact ...
Despite a fitness cost imposed on bacterial hosts, large conjugative plasmids play a key role in the diffusion of resistance determinants, such as CTX-M extended-spectrum beta-lactamases. Among the large conjugative plasmids, IncF plasmids are the most predominant group, and an F2A1B- IncF-type plasmid encoding a CTX-M-15 variant was recently described as being strongly associated with the emerging worldwide Escherichia coli sequence type 131 (ST131)-O25bH4 H30Rx/C2 sublineage. In this context, we investigated the fitness cost of narrow-range F-type plasmids, including the F2A1B- IncF-type CTX-M-15 plasmid, and of broad-range C-type plasmids in the K-12-like J53-2 E. coli strain. Although all plasmids imposed a significant fitness cost to the bacterial host immediately after conjugation, we show, using an experimental-evolution approach, that a negative impact on the fitness of the host strain was maintained throughout 1,120 generations with the IncC-IncR plasmid, regardless of the presence or absence
ESCAPPM or ESCHAPPM is a mnemonic for the organisms with inducible beta-lactamase activity that is chromosomally mediated. E: Enterobacter spp. S: Serratia spp. C: Citrobacter freundii H: Hafnia spp. A: Aeromonas spp.[citation needed] P: Proteus spp. (P. vulgaris) P: Providencia spp. M: Morganella morganii In vitro sensitivities are not applicable in vivo. In general, treatment with cephalosporins results in inducible beta-lactamase activity. Treatment with an aminoglycoside or carbapenem is usually indicated. Carbapenems are a class of beta-lactam antibiotics with a broad spectrum of antibacterial activity. They have a structure that renders them highly resistant to beta-lactamases. Examples of Carbapenems include meropenem and imipenem. Feedback for Practical 10: Antimicrobial Agents. Archived from the original on July 23, 2005. Retrieved 2010-01-26. CS1 maint: BOT: original-url status unknown (link ...
Concluding remarks.The rising incidence of ESBL- and KPC-producing pathogens presents challenges in the empirical therapy for Gram-negative bacterial infections. Acknowledging the increased mortality rates with ineffective initial therapy (13, 16), the timely recognition of ESBL- and KPC-producing organisms may have a positive impact on clinical outcomes. Nucleic acid microarrays can be important in achieving this end.. In this study, the nucleic acid microarray technology (Check-KPC/ESBL kits) demonstrated accurate and reproducible results with regard to the presence of ESBL and KPC genes within the Enterobacteriaceae (2, 3, 8, 9). Current practice requires 24 h of adequate growth prior to testing on the microarray system. Our study shows that the Check-KPC/ESBL kit could be employed with DNA extracted directly from blood cultures before species identification. This could reduce the notification time by as much as 18 to 20 h. Depending on the method used, the time savings, costs of materials, ...
We investigated the general level of antibiotic resistance with further analysis of extended-spectrum beta-lactamase (ESBL) prevalence, as well as the population structure of E. coli in fecal flora of humans and Franklins gulls (Leucophaeus pipixcan) in central parts of Chile. We found a surprisingly high carriage rate of ESBL-producing E. coli among the gulls 112/372 (30.1%) as compared to the human population 6/49 (12.2%.) Several of the E. coli sequence types (STs) identified in birds have previously been reported as Multi Drug Resistant (MDR) human pathogens including the ability to produce ESBLs. This means that not only commensal flora is shared between birds and humans but also STs with pathogenic potential. Given the migratory behavior of Franklins gulls, they and other migratory species, may be a part of ESBL dissemination in the environment and over great geographic distances. Apart from keeping the antibiotic use low, breaking the transmission chains between the environment and ...
Table 4: Association between Virulence Factors and Extended Spectrum Beta-Lactamase Producing|i| Klebsiella pneumoniae|/i| Compared to Nonproducing Isolates
en] The Bacillus licheniformis BS3 beta-lactamase catalyzes the hydrolysis of the beta-lactam ring of penicillins, cephalosporins, and related compounds. The production of beta-lactamases is the most common and thoroughly studied cause of antibiotic resistance. Although they escape the hydrolytic activity of the prototypical Staphylococcus aureus beta-lactamase, many cephems are good substrates for a large number of beta-lactamases. However, the introduction of a 7alpha-methoxy substituent, as in cefoxitin, extends their antibacterial spectrum to many cephalosporin-resistant Gram-negative bacteria. The 7alphamethoxy group selectively reduces the hydrolytic action of many beta-lactamases without having a significant effect on the affinity for the target enzymes, the membrane penicillin-binding proteins. We report here the crystallographic structures of the BS3 enzyme and its acyl-enzyme adduct with cefoxitin at 1.7 Angstrom resolution. The comparison of the two structures reveals a covalent ...
BACKGROUND AND OBJECTIVES: Bacteraemia caused by Enterobacteriaceae (EB) producing extended-spectrum ?-lactamase (ESBL+) has been associated with higher mortality compared with non-ESBL-producing (ESBL-) EB bacteraemia in observational studies. We conducted a systematic review and meta-analysis of these studies to assess how adjusting for confounding in multivariate analyses affects the pooled estimate, and whether multivariate analyses that include intermediates in the causal pathway of outcome (sepsis severity and inadequate empirical therapy) have lower estimates of attributable mortality. DATA SOURCES: PubMed search on 23 November 2010 followed by manually searching reference lists of included studies. STUDY ELIGIBILITY CRITERIA: Cohort studies published in English with separate mortality rates for ESBL+ and ESBL- EB bacteraemia. SYNTHESIS METHODS: Random-effects pooling of unadjusted and adjusted ORs followed by subgroup analyses to explore effects of adjustment procedures on adjusted ORs. ...
Because of the popularity of beta-lactam drugs, certain bacteria have been able to develop counter-measures to traditional drug therapies. An enzyme called beta-lactamase is present in many different types of bacteria, which serves to break the beta lactam ring, which effectively nullifies the antibiotics effectiveness. An example such enzyme is the NDM-1 discovered in 2009.. As a response to bacterial resistance to beta-lactam drugs, there are drugs, such as Augmentin/CLA, that are designed to disable the beta-lactamase enzyme. Augmentin/CLA (FGP) is made of amoxicillin, a beta-lactam antibiotic, and clavulanic acid, a beta-lactamase inhibitor. The clavulanic acid is designed to overwhelm all beta-lactamase enzymes, bind irreversibly to them, and effectively serve as an antagonist so that the amoxicillin is not affected by the beta-lactamase enzymes.. Full article ▸. ...
Pseudomonas aeruginosa is a leading cause of infections especially in patients with weakened immune systems. This pathogen is intrinsically resistant to many antibacterial agents.The aim of this study was to survey the antibiotic resistance pattern and frequency of bla OXA10 gene in Carbapenemase Producing P. aeruginosa isolated from patients in Isfahan hospitals.Total of 100 clinical isolates of P. aeruginosa from different samples were collected. Antibiotic susceptibility for antimicrobial agents was carried out according to the clinical and laboratory standards institute (CLSI) guidelines, and the frequency of the gene encoding bla OXA10 was studied by polymerase chain reaction (PCR).The resistance rate of the isolated strains to certain antibiotics wasas following: ciprofloxacin (56%), gentamicin (59%), tobramycin (61%), amikacin (65%), imipenem (55%), cefepime (55%), ceftazidime (57%), ceftriaxone (60%), cefotaxime (62%), oxacillin (100%), and piperacillin (48%), respectively. P. aeruginosa
There are currently a total of 6 beta-lactam + beta-lactamase inhibitor combinations in clinical trials. It will be a steep learning curve for the pharma reps (and physicians) to understand the resistance classifications, the confusing ESBL definitions, the CRE nomenclature, Continue reading What is the Niche for Ceftolozane / Tazobactam?→. ...
Pseudomonas aeruginosa is a Gram negative aerobic rod shaped bacterium and is an opportunistic pathogen that usually causes nosocomial infection in immunocompromised patient with various infections and affects normal healthy human as well. P. aeruginosa is also an omnipresent pathogen that can be inhabited in soil, water, vegetable, human and animal. Metallo-β-lactamases (MBL) producing P. aeruginosa are known to be resistant to almost the entire anti-pseudomonas agent via mechanism of low outer membrane permeability, β-lactamases synthesis and the efflux systems. This study was conducted to detect the potential of metallo-β-lactamases producing P. aeruginosa presence in water samples from various parts of Malaysia. In this study, 52 water samples were collected from various parts of Malaysia. These P. aeruginosa isolates were processed to these phenotypic methods, Hodge test which is used to detect the carbapenemase production, Imipenem- EDTA combined disc test (CDT). Imipenem-EDTA
The emergence and global spread of carbapenemase-producing Enterobacteriaceae is of great concern to health services worldwide. These bacteria are often resistant to all beta-lactam antibiotics and frequently co-resistant to most other antibiotics, leaving very few treatment options. The epidemiology is compounded by the diversity of carbapenem-hydrolysing enzymes and the ability of their genes to spread between different bacterial species. Difficulties are also encountered by laboratories when trying to detect carbapenemase production during routine diagnostic procedures due to an often heterogeneous expression of resistance. Some of the resistance genes are associated with successful clonal lineages which have a selective advantage in those hospitals where antimicrobial use is high and opportunities for transmission exist; others are more often associated with transmissible plasmids. A genetically distinct strain of Klebsiella pneumoniae sequence type (ST) 258 harbouring the K. pneumoniae
Extended Spectrum Beta-Lactamase-producing Enterobacteriaceae (ESBL-PE) are an emerging concern in public health. Antimicrobial use, hospitalization and foreign travel are associated with human carriage of ESBL-PE. Duration of carriage with ESBL-PE can vary. The main objective of this thesis is to provide an overview of the current scientific knowledge on persistence ... read more of ESBL carriage in humans. In addition, risk factors for duration of ESBL carriage will be described. After a literature search, 14 studies met the criterion that duration of ESBL-PE was assessed. Eight studies were conducted in patients, two in NICU patients, and four in non-patients (travelers, adopted children, medical students). Approximately half of adult (hospitalized) patients carried ESBL-PE after 6 months (range 33-53%). After 12 months, this percentage was around 25%. Median carriage time was reported from 98 days till more than 9 months. For a minority of patients carriage time was more than three years. ...
Extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae are often susceptible in vitro to β-lactam/β-lactamase inhibitor (BLBLI) combination antibiotics, but their use has been limited by concerns of clinical inefficacy. We aimed to compare outcomes between patients treated with BLBLIs and carbapenems for bloodstream infection (BSI) caused by cefotaxime non-susceptible (likely ESBL- or AmpC β-lactamase-producing) Escherichia coli and Klebsiella pneumoniae.All adult patients with a BSI caused by cefotaxime non-susceptible E. coli or K. pneumoniae were included from May 2012-May 2013. We compared outcomes between patients who had definitive monotherapy with a carbapenem to those who had definitive monotherapy with a BLBLI.There were 92 BSIs that fulfilled the microbiological inclusion criteria. 79 (85.9%) were caused by E. coli and 13 (14.1%) by K. pneumoniae. Four out of 23 (17.4%) patients treated with carbapenem monotherapy and 2 out of 24 (8.3%) patients treated with BLBLI monotherapy
The purpose of the study was to evaluate how use of antibiotics precedes the presence of ESBL-producing E.coli in general practice. The authors performed a triple-case-control study where three case groups were individually compared to a single control group of uninfected individuals. Urine samples were prospectively collected and retrospective statistical analyses were done. This study included 98 cases with urinary tract infection (UTI) caused by ESBL-producing E. coli, 174 with antibiotic-resistant (non-ESBL) E. coli, 177 with susceptible E. coli and 200 with culture negative urine samples. Case groups had significantly higher use of antibiotics than the control group within 30 days before infection (p , 0.0001). The ESBL group had significantly more hospital admissions than the other case groups (p , 0.05). Hospital admission was an independent risk factor for community onset UTI by ESBL-producing E. coli. Exposure to antibiotics was a risk factor for UTI with E. coli, while prior antibiotic ...
The range of antibiotics available to combat bacterial infectious diseases is diminishing due to the development of resistance to all classes of antibiotics. The emergence of Carbapenem-resistant Enterobacteriaceae (CRE) is one of the most significant and urgent threats to global human health. CRE strains that have acquired and expressed genes encoding for extended-spectrum β-lactamases with carbapenemase activity have now been reported across the globe. One strategy for prolonging the use of existing antibiotics has been to develop adjuvants that inhibit the function of β-lactamases and thus restore the bacterias sensitivity to the β-lactam antibiotic (e.g. clavulanic acid and tazobactam). However, for carbapenemase enzymes which are class B β-lactamases (i.e. the metallo-β-lactamases (MBLs)), such inhibition strategies have, so far, been ineffective.. Consequently, there is a market need for effective inhibitors of class B MBLs as adjuvants for carbapenems. These MBL inhibitors have the ...
Simplified Selective Digestive Tract Decontamination for the prevention of ICU infections in a setting of high-level antibiotic resistance. Scientific Background:. Aerobic gram-negative bacilli (AGNB), Gram-positive bacteria and fungi are responsible for hospital acquired infections. This problem is especially typical in intensive care units (ICUs) due to the complexity of disease and wide use of invasive procedures. The common use of empiric wide-range antibiotic therapy had lead to the development significant resistance of these pathogens and this group of bacteria was defined as Multi-Drug Resistant Organisms (MDRO). Among these bacteria the most important and virulent are: Carbapenem Resistant Enterobacteriaceae (CRE), Extended Spectrum Beta Lactamases (ESBL), Methicillin Resistant Staphylococcus Aureus (MRSA), Vancomycin Resistant Enterococci (VRE) as well as Fluconazol resistant Candida.. The main reservoir of these organisms is the intestinal tract, which raises the possibility that their ...
Antimicrobial stewardship programs (ASPs) focus on improving the utilization of broad spectrum antibiotics to decrease the incidence of multidrug-resistant Gram positive and Gram negative pathogens. Hospital admission for both medical and surgical intra-abdominal infections (IAIs) commonly results in the empiric use of broad spectrum antibiotics such as fluoroquinolones, beta-lactam beta-lactamase inhibitors, and carbapenems that can select for resistant organisms. This review will discuss the management of uncomplicated and complicated IAIs as well as highlight stewardship initiatives focusing on the proper use of broad spectrum antibiotics.
UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
Author: MEHRUNNISA J., , THYGARAJAN RAVINDER, RADHIKA KATRAGADDA. Category: Microbiology. [Download PDF]. Abstract:. The purpose of the study is to detect Metallobetalatamase (MBL) producing GNB (Gram Negative Bacilli) isolated from various clinical samples received in the Department of Microbiology, Kilpauk Medical College & Hospital, Chennai. All the isolates that were resistant to ceftazidime collected and MBL production was demonstrated by combined disc test with EDTA and double disc synergy test. Among the GNBs isolated from clinical samples, 41 % showed resistance to ceftazidime. These GNBs which were resistant to ceftazidme were tested for MBL production, 29% were found to be MBL producers. These 29% of MBL producers showed resistance to commonly used antibiotics. Thus, MBL producers are seen not only among non fermenters like pseudomonas aeruginosa but also produced by Enterobacteriaceae causing problems in treating patients with infections.. Keywords: Ceftazidime (CAZ) ...
NDM-1 (New Delhi metallo-beta-lactamase) gene encodes a metallo-beta-lactamase (MBL) with high carbapenemase activity, which makes the host bacterial strain easily dispatch the last-resort antibiotics
Oxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name penicillin can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Oxacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Oxacillin results from the inhibition of cell wall synthesis and is mediated through Oxacillin binding to penicillin binding proteins (PBPs). Oxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases ...
Among 177 carbapenemase-producing Gram-negative bacilli (108 KPC 32 NDM 11 IMP 8 OXA-48 4 OXA-181 2 OXA-232 5 IMI 4 VIM and 3 SME producers) aztreonam-avibactam was energetic against all isolates except two NDM producers with elevated MICs of 8/4 and 16/4 mg/liter; ceftazidime-avibactam was active against all KPC- IMI- SME- and most OXA-48 group-producing isolates (93%) but not metallo-β-lactamase makers. and certain class D β-lactamases by covalent acylation of the β-lactamase active site serine residue. It restores susceptibility of harboring extended-spectrum β-lactamases (ESBLs) AmpC cephalosporinases and class A carbapenemases to ceftazidime or ceftaroline (1). studies of avibactam in combination with aztreonam have also proven activity against harboring NDM (a class B metallo-β-lactamase); however you will find scant data for the additional less commonly experienced carbapenemases (2 -4). The aim of this study was to examine the activities of ceftazidime and aztreonam with and without ...
A new series of phosphonyl derivatives has been prepared and tested for inhibition of serine (classes A and C) beta-lactamases. The results were compared with those previously acquired with aryl phosphonate monoesters and with alkaline hydrolysis rates. A methyl p-nitrophenyl phosphate monoanion was markedly poorer as an inhibitor of the class C beta-lactamase of Enterobacter cloacae P99 than a comparable p-nitrophenyl phosphonate. Phosphonyl fluorides, thiophenyl esters, N-phenylphosphonamidates and a p-nitrophenyl thionophosphonate were, in general, comparable with p-nitrophenyl phosphonates in inhibitory power. The incorporation of a specific amino side chain led to an increase in the rates of inhibition of around 10(4)-fold. Apparently unresponsive to the addition of the side chain to the enzyme was N-phenyl methylphosphonamidate, where binding of the side chain may interfere with access of the leaving group to a proton which is necessary to active-site phosphonylation and inhibition. ...
Beta-lactamases are the most widespread resistance mechanism to beta-lactam antibiotics and are an increasing menace to public health. Several beta-lactamase structures have been determined, making this enzyme an attractive target for structure-based drug design. To facilitate inhibitor design for t …
"Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical ... Jacoby GA, Tran J (July 1999). "Sequence of the MIR-1 beta-lactamase gene". Antimicrobial Agents and Chemotherapy. 43 (7): 1759 ...
Metallo-beta-lactamases: a last frontier for beta-lactams? Lancet Infectious Diseases. 11 (5), 381-393 (2011). Deshpande LM, ... Extended-spectrum beta-lactamases: a clinical update. Clinical Microbiology Reviews. 18, 657-686 (2005). Jiang X, Ni Y, Jiang Y ... Metallo-beta-lactamase-producing Enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in ... Characterization of a new metallo-beta-lactamase gene, bla NDM-1, and a novel erythromycin esterase gene carried on a unique ...
Beta-lactamase. Lyase (EC 4). *4.1 Dopa decarboxylase. *4.2 Carbonic anhydrase. Miscellaneous. *Steroidogenesis inhibitor ...
Beta-lactamase. Lyase (EC 4). *4.1 Dopa decarboxylase. *4.2 Carbonic anhydrase. Miscellaneous. *Steroidogenesis inhibitor ...
Beta-lactamase. Lyase (EC 4). *4.1 Dopa decarboxylase. *4.2 Carbonic anhydrase. Miscellaneous. *Steroidogenesis inhibitor ...
"Protein prenylation in glucose-induced insulin secretion from the pancreatic islet beta cell: a perspective". Journal of ...
Beta-lactamase. Lyase (EC 4). *4.1 Dopa decarboxylase. *4.2 Carbonic anhydrase. Miscellaneous. *Steroidogenesis inhibitor ...
Beta-lactamase. Lyase (EC 4). *4.1 Dopa decarboxylase. *4.2 Carbonic anhydrase. Miscellaneous. *Steroidogenesis inhibitor ...
Beta-lactamase. Lyase (EC 4). *4.1 Dopa decarboxylase. *4.2 Carbonic anhydrase. Miscellaneous. *Steroidogenesis inhibitor ...
Beta-lactamases BRO-1 and BRO-2 have been shown to be transported by the TAT pathway. Other potential passenger proteins ... The beta-lactamases are produced in the cytoplasm and translocated to the periplasmic space by twin-arginine translocation ... Also, the resistance of M. catarrhalis to other antibiotics may be attributed to beta-lactamase, as well, because the use of ... Many laboratories also perform a butyrate esterase test and a beta-lactamase test. Both tests should be positive and can help ...
Extended Spectrum Beta-Lactamase), MBL (Metallo Beta-Lactamase), AmpC Beta-Lactamase and VISA/h VISA]. Etest has been FDA ...
Acetylcholine releasing agents: Alpha-Latrotoxin • Beta-Bungarotoxin; Acetylcholine release inhibitors: سم بوتولینوم (Botox); ... Dihydro-beta-erythroidine • Dimethyltubocurarine (Metocurine) • Dipyrandium • Dizocilpine (MK-801) • Doxacurium • Duador • ... beta-Methylphenethylamine • Benzodioxolylbutanamine • Benzphetamine • Benzodioxolylhydroxybutanamine • Buphedrone • Butylone • ...
The CSP-1 beta- lactamaseEdit. In 2005, Handal et al. (2005b) identified a novel Ambler class A beta-lactamase called CSP-1 ... Following the characterization of CfxA beta- lactamase in B. vulgatus and CfxA2 beta-lactamase in P. intermedia (nucleotide ... This resistance is often linked to the production of beta- lactamases. Most beta-lactamases identified in Bacteroides, ... The high frequency of strains producing beta-lactamase limit the use of single beta-lactam antibiotics as first-line treatment ...
As a result, amoxicillin-clavulanate (a beta-lactamase inhibitor/penicillin combination) is seen as the treatment of choice. P ...
... in which six research groups attempted to predict the complexed structure of TEM-1 Beta-lactamase with Beta-lactamase inhibitor ... "Molecular Docking Programs Successfully Predict the Binding of a Beta-lactamase Inhibitory Protein to TEM-1 Beta-Lactamase". ...
March 2008). "Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure". ... Tazobactam is a potent β-lactamase inhibitor of most common class A and C β-lactamases. Tazobactam has little clinically ... "Three decades of beta-lactamase inhibitors". Clinical Microbiology Reviews. 23 (1): 160-201. doi:10.1128/CMR.00037-09. PMC ... with the MIC90 for extended spectrum beta-lactamase expressing Klebsiella pneumoniae being ,32 μg/mL. ...
Bush, K (Jan 1988). "Beta-lactamase inhibitors from laboratory to clinic". Clin Microbiol Rev. 1 (1): 109-123. PMC 358033 . ... Beta-lactam bacterial resistance can also be dealt with by administering beta-lactam antibiotics with drugs that block beta- ... can be circumvented by using antibiotics such as nafcillin that are not susceptible to destruction by certain beta-lactamases ( ... For example, bacterial resistance against beta-lactam antibiotics (such as penicillins and cephalosporins) ...
1995). "AmpD, essential for both beta-lactamase regulation and cell wall recycling, is a novel cytosolic N-acetylmuramyl-L- ...
An example of a narrow spectrum antibiotic is Dicloxacillin, which acts on beta-lactamase-producing Gram-positive bacteria such ...
Park JH, Back JH, Hahm SH, Shim HY, Park MJ, Ko SI, Han YS (October 2007). "Bacterial beta-lactamase fragmentation ... Remy I, Ghaddar G, Michnick SW (2007). "Using the beta-lactamase protein-fragment complementation assay to probe dynamic ... such as dihydrofolate reductase or beta-lactamase respectively, or proteins that give colorimetric or fluorescent signals are ... LacZ (beta-galactosidase)[10]. *Luciferase,[11][12] including ReBiL (recombinase enhanced bimolecular luciferase)[13] and ...
Beta-lactamase inhibitors, such as clavulanic acid and sulbactam[138]. Metabolic stimuli such as sugar can help eradicate a ... "Three decades of beta-lactamase inhibitors". Clinical Microbiology Reviews. 23 (1): 160-201. doi:10.1128/CMR.00037-09. PMC ... Ceftolozane/tazobactam (CXA-201; CXA-101/tazobactam): Antipseudomonal cephalosporin/β-lactamase inhibitor combination (cell ... Ceftaroline/avibactam (CPT-avibactam; ceftaroline/NXL104): Anti-MRSA cephalosporin/ β-lactamase inhibitor combination (cell ...
Both narrow spectrum beta-lactamases (e.g. penicillinases) and extended spectrum beta-lactamases (ESBL) are common for ... Often multiple beta-lactamase genes are found on the same plasmid hydrolyzing a wide spectrum of beta-lactam antibiotics. ESBL ... The first clinically observed ESBL enzymes were mutated versions of the narrow spectrum beta-lactamases, like TEM and SHV. ... Oktem IM, Gulay Z, Bicmen M, Gur D (January 2008). "qnrA prevalence in extended-spectrum beta-lactamase-positive ...
... sodium is a narrow-spectrum[1] beta-lactam antibiotic[2] of the penicillin class. As a beta-lactamase-resistant ... a reversible suicide inhibitor of beta-lactamase". Biochem. J. 281 (1): 191-6. doi:10.1042/bj2810191. PMC 1130660. PMID 1731755 ...
"Molecular basis of beta-lactamase induction in bacteria". 》Antimicrob. Agents Chemother.》 37 (2): 153-8. doi:10.1128/aac.37.2. ... Okada S, O'Brien JS (August 1969). "Tay-Sachs disease: generalized absence of a beta-D-N-acetylhexosaminidase component". 》 ... Fisher JF, Meroueh SO, Mobashery S (February 2005). "Bacterial resistance to beta-lactam antibiotics: compelling opportunism, ...
Hall, Alan; Knowles, Jeremy (23 December 1976). "Directed selective pressure on a beta-lactamase to analyse molecular changes ... Hall's PhD was on the enzymology of B-lactamase, which led to his first paper being published in Nature in 1976. He used ... Direct selection on these mutants allowed catalytic properties of B-lactamase to be identified and allowed structure-function ... strains of E. Coli with mutated B-lactamase, an antibiotic resistance enzyme, and assayed their activity in the presence of ...
"Thiol-beta-lactamase: replacement of the active-site serine of RTEM beta-lactamase by a cysteine residue". Proceedings of the ... a variant of TEM1 β-lactamase with 5 mutations is able to cleave cefotaxime (a third generation antibiotic).[36] However, of ...
In 2016, a synthetic peptide-conjugated PMO (PPMO) was found to inhibit the expression of New Delhi metallo-beta-lactamase, an ... In contrast to other beta-lactams, it is highly resistant to degradation by β-lactamases or cephalosporinases. In general, ... It works against extended-spectrum β-lactamases, but may be more susceptible to metallo-β-lactamases.[6] Meropenem is ... resistance arises due to mutations in penicillin-binding proteins, production of metallo-β-lactamases, or resistance to ...
They are categorized under EC number EC 3.5.1 and 3.5.2. Examples include: Beta-lactamase Histone deacetylase Urease The ...
Two different bonds in beta-lactams can be cleaved (1 by penicillin acylase and 2 by beta-lactamase). ... 1992). "Beta-lactamase TEM1 of E. coli. Crystal structure determination at 2.5 A resolution". FEBS Lett. 299 (2): 135-42. doi: ... "The catalytic mechanism of beta-lactamases: NMR titration of an active-site lysine residue of the TEM-1 enzyme". Proc. Natl. ... Archaean proteasome, beta component (Thermoplasma acidophilum) PE clan. T5. Ornithine acetyltransferase (Saccharomyces ...
Some of the more-studied resistance mechanisms include: utilization of beta-lactamases, which are able to cleave penicillins, ...
NDM-1, New Delhi-metallo-beta-lactamase 1-producerende enterobakterier (Klebsiella pneumoniae, E. coli, Vibrio colerae og ... www.ugeskriftet.dk/LF/UFL/2012/12/pdf/VP61398.pdf New Delhi-metallo-beta-laktamase 1 - en uønsket souvenir. Ugeskrift for Læger ...
Presumably penicillin G could be given with a beta-lactamase inhibitor combination, such as Unasyn, for patients with a beta- ... Antibiotics that contain beta-lactamase inhibitors (i.e., oral Augmentin or parenteral Unasyn) cover C. canimorsus as well as ... After diagnosis, provided the strain is not beta-lactamase producing, medication should be switched to penicilin G. ... lactamase producing strain. Mortality of meningitis-related infections is much lower than mortality associated with septicemia ...
... stereoisomers were also reported to inhibit some metallo-β-lactamases. Captopril was developed in 1975 by three ... BETA.-hydroxy acid". Chem. Pharm. Bull. 30 (9): 3139-3146. doi:10.1248/cpb.30.3139. M. A. Ondetti, D. W. Cushman, DE 2703828 ; ... "Structural Basis of Metallo-β-Lactamase Inhibition by Captopril Stereoisomers". Antimicrobial Agents and Chemotherapy. 60 (1): ...
Beta-lactamase. 3.5.3: Linear amidines/. Ureohydrolases. *Arginase. *Agmatinase. *Protein-arginine deiminase ...
Beta-lactamase. *Dihydroorotase. 3.5.3: Linear amidines/. Ureohydrolases. *Arginase. *Agmatinase. *Protein-arginine deiminase ...
New Delhi metallo-beta-lactamase 1 (NDM-1) and Verona integron-encoded metallo-beta-lactamase (VIM-2), and make those ... "Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance". Nature. 510 (7506): 503-506. Bibcode:2014Natur.510 ...
Penicillin and penicillin-derived antibiotics can thus be combined with a beta-lactamase inhibitor such as clavulanic acid or ... Fusobacterium necrophorum is generally highly susceptible to beta-lactam antibiotics, metronidazole, clindamycin and third ... generation cephalosporins while the other fusobacteria have varying degrees of resistance to beta-lactams and clindamycin.[12] ...
32 comp CD (P.T., 2002) Lactamase Bonus Compilation Charalambides at Wholly Other Charalambides at Kranky Interview with the ... "/"Sun or Wind" 7" (Timelag, 2002) Ana/Kata 10" EP (Beta-lactam Ring Records, 2002) 'Charalambides / Pocahaunted - Split (7", ...
AMPICILLIN:(BETA LACTAMASE) = Zîndedijek ji penîsîlîn lêwergirtî ye. Ew zorbuna bektîrya berbend dike bi têhelkeşa bi pêkînanê ...
Three decades of beta-lactamase inhibitors»։ Clinical Microbiology Reviews 23 (1): 160-201։ January 2010։ PMC 2806661։ PMID ...
Beta-lactamase test. *Disk diffusion test. *Etest. *McFarland standards. *Minimum inhibitory concentration ...
Beta-lactamase test. *Disk diffusion test. *Etest. *McFarland standards. *Minimum inhibitory concentration ...
It is not active against beta-lactamase-producing bacteria, which include many strains of Staphylococci.[11] ... It is in the penicillin and beta lactam family of medications.[3] It usually results in bacterial death.[3] ...
... with the MIC90 for extended spectrum beta-lactamase (ESBL) expressing Klebsiella pneumonia being ,32 μg/mL. ... Ceftolozane is combined with the β-lactamase inhibitor tazobactam, which protects ceftolozane from degradation.[2][3][4][5][6] ... including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice". Antimicrobial Agents and ... A novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli". Drugs ...
Clindamycin, or a combination of metronidazole and a macrolide, or a penicillin combined with a beta-lactamase inhibitor is ... or a combination of a penicillin and a beta-lactamase inhibitor.[4] However, in patients with a penicillin allergy, clindamycin ... are exhibiting an increased resistance based on the production of beta-lactamase.[4] Patients who have undergone recent ... penicillin therapy have demonstrated an increase in beta-lactamase-producing (anaerobic and aerobic) bacteria. ...
β-Lactamase-resistant semisynthetic penicillins such as methicillin (and its successors, nafcillin and cloxacillin) were ... For treatment of infections caused by Gram-positive microorganisms in patients with serious allergies to beta-lactam ...
Beta lactamase inhibitors irreversibly bind to beta-lactamase preventing it from breaking down the beta-lactam rings on the ... against beta-lactamase producing bacteria due to an acyl side chain that protects the beta-lactam ring from beta-lactamase.[13] ... beta-lactamase inhibitors, alongside penicillin gives penicillin activity against beta-lactamase producing bacteria. ... Some bacteria produce enzymes that break down the beta-lactam ring, called beta-lactamases, which make the bacteria resistant ...
Beta-lactamase test. *Disk diffusion test. *Etest. *McFarland standards. *Minimum inhibitory concentration ...
Escherichia coli and other species of Enterobacteriaceae producing CTX-M type extended-spectrum beta-lactamases (ESBLs) have ... Laboratory detection of bacteria with extended-spectrum beta-lactamases * A Johnson, N Woodford, D Livermore ... Escherichia coli and other species of Enterobacteriaceae producing CTX-M type extended-spectrum beta-lactamases (ESBLs) have ... Laboratory detection of bacteria with extended-spectrum beta-lactamases. Euro Surveill. 2004;8(28):pii=2502. https://doi.org/ ...
... non-O139 belongs to a family of cassette-encoded beta-lactamases ... CARB-9 beta-lactamases: a carbenicillinase encoded in the VCR ... CARB-9 beta-lactamases. Subscribe to New Research on CARB-9 beta-lactamases ... non-O139 belongs to a family of cassette-encoded beta-lactamases ...
Sebastian Amyes on Beta-lactamases: clinical impact and epidemiology, part of a collection of online lectures. ... Most of the beta-lactamases Im going to talk about are in Gram-negative bacteria. There are, of course, beta-lactamases in ... the impact of beta-lactamases and outline some of the most important beta-lactamases that were having to deal with in the ... The transferable class C beta-lactamases and what we know as extended-spectrum beta-lactamases. Also, Im going to talk about ...
beta Lactamase Monoclonal Antibody from Invitrogen for Western Blot and ELISA applications. This antibody reacts with Bacteria ... Bacterial resistance to beta lactams continues to increase, primarily due to the production of beta lactamases. Beta lactamases ... Cite beta Lactamase Monoclonal Antibody. The following antibody was used in this experiment: beta Lactamase Monoclonal Antibody ... beta lactamases have point mutations in structural genes that have extended the substrate specificity of these beta lactamases ...
... beta]-lactamase producers, United States.(LETTERS, Letter to the editor) by Emerging Infectious Diseases; Health, general ... Controversies about Extended-Spectrum and AmpC Beta-Lactamases.. Expanded-spectrum [beta]-lactamase and plasmid-mediated ... Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18: 657-86. (2.) Livermore DM, Canton R, ... APA style: Community-acquired extended-spectrum [beta]-lactamase producers, United States.. (n.d.) >The Free Library. (2014). ...
Mercks Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and ...
producing extended-spectrum beta-lactamases and plasmid-mediated AmpC in Mozambican university students, BMC Infectious ... Analysis of beta-lactamase phenotypes and carriage of selected beta-lactamase genes among Escherichia coli strains obtained ... Kiiru J, Kariuki S, Goddeeris BM, Butaye P. Analysis of beta-lactamase phenotypes and carriage of selected beta-lactamase genes ... Kiiru J, Kariuki S, Goddeeris BM, Butaye P. Analysis of beta-lactamase phenotypes and carriage of selected beta-lactamase genes ...
Extended Spectrum Beta Lactamases Detection and Multiple Antibiotic Resistance Indexing of Escherichia Coli from Urine Samples ... Chakrawarti, A., Dongol, P., Khanal, H., Subba, P., & Benerjee, J. (2015). Extended Spectrum Beta Lactamases Detection and ... Multidrug resistance bacteria have limited the therapeutic possibilities by producing Extended Spectrum Beta Lactamases (ESBL ...
... Kevin R Forward Department of Pathology and Laboratory Medicine, Queen Elizabeth II Health ... Kevin R Forward, "Extended-Spectrum Beta-Lactamases," Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 17 ...
... Kevin R Forward Department of Pathology and Laboratory Medicine, Queen Elizabeth II Health ... The definition of extended-spectrum beta-lactamases (ESBLs) has expanded rapidly, in terms of both the number and the variety ...
Klebsiella and extended spectrum beta-lactamases.. Urban C1, Rahal JJ.. Author information. 1. Department of Medicine, The New ... hydrolyzing enzymes has broadened the spectrum of primitive beta-lactamases allowing inactivation of a wide variety of beta- ... A growing number of newly identified plasmid encoded beta-lactam ...
Extended-spectrum beta-lactamases are specific enzymes released by a bacteria that neutralizes the effects of antibiotics. ... Extended-spectrum beta-lactamases. Retrieved from https://www.uptodate.com/contents/extended-spectrum-beta-lactamases ... Extended-spectrum beta-lactamases, or ESBLs, are enzymes produced by certain types of bacteria. These enzymes can break down ... "What are extended-spectrum beta-lactamases (ESBL)?." Medical News Today. MediLexicon, Intl., 26 Sep. 2017. Web.. 22 Apr. 2019 ...
beta-Lactamases: protein evolution in real time.. Petrosino J1, Cantu C 3rd, Palzkill T. ... One ongoing example of these mechanisms is the evolution of new variants of the TEM and SHV beta-lactamases with altered ... The evolution and spread of bacteria resistant to beta-lactam antibiotics has progressed at an alarming rate. Bacteria may ...
Species: Beta-lactamase-related (IPR001466). Key Species. Key species. Number of proteins. FASTA. Protein IDs. ...
Belongs to the class-D beta-lactamase family.UniRule annotation. Automatic assertion according to rulesi ... IPR012338, Beta-lactam/transpept-like. IPR002137, Beta-lactam_class-D_AS. IPR001460, PCN-bd_Tpept. ... IPR012338, Beta-lactam/transpept-like. IPR002137, Beta-lactam_class-D_AS. IPR001460, PCN-bd_Tpept. ... tr,A0A1C9C4P5,A0A1C9C4P5_9PAST Beta-lactamase OS=Gallibacterium anatis OX=750 PE=3 SV=1 ...
Crystal structure and kinetic analysis of beta-lactamase inhibitor protein-II in complex with TEM-1 beta-lactamase.. Nat. ... The beta-lactamase-inhibitor protein (BLIP) is produced by Streptomyces species. BLIP acts as a potent inhibitor of beta- ... the beta-hairpin loop from domain 1 inserting into the active site of beta-lactamase [PMID: 8605632]. BLIP shows no sequence ... A potent new mode of beta-lactamase inhibition revealed by the 1.7 A X-ray crystallographic structure of the TEM-1-BLIP complex ...
This is the first report of NDM-1 in the United States, and the first report of metallo-beta-lactamase carriage among ... Detection of Enterobacteriaceae Isolates Carrying Metallo-Beta-Lactamase --- United States, 2010. During January--June 2010, ... the New Delhi metallo-beta-lactamase (NDM-1) (1), were identified from three U.S. states at the CDC antimicrobial ... Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique ...
Compare cephalosporins/beta-lactamase inhibitors. View important safety information, ratings, user reviews, popularity and more ... Beta-lactamase inhibitors block the activity of beta-lactamase enzymes. Some species of bacteria produce beta-lactamase enzymes ... beta-lactamase inhibitors are administered with the beta-lactam antibiotics so the action of beta-lactamase is inhibited. This ... Cephalosporins/beta-lactamase inhibitors. What are Cephalosporins/beta-lactamase inhibitors?. Cephalosporins are a group of ...
A beta-lactam + H2O = a substituted beta-amino acid. UniProt ...
Beta-lactamase SHV-1. A. 286. Klebsiella pneumoniae. Mutation(s): 1 Gene Names: bla, shv1. EC: 3.5.2.6. ... Ligand-dependent disorder of the Omega loop observed in extended-spectrum SHV-type beta-lactamase.. Sampson, J.M., Ke, W., ... CYCLOHEXYL-HEXYL-BETA-D-MALTOSIDE. C24 H44 O11. WUCWJXGMSXTDAV-QKMCSOCLSA-N. Ligand Interaction. ... We also studied the inactivation of the R164H and R164S mutants with tazobactam and SA2-13, a unique β-lactamase inhibitor that ...
Beta-lactamase. Kind. protein. Organism. Bacillus licheniformis. Polypeptides. Name. UniProt ID. Beta-lactamase. P00808. ...
Beta-lactamases explanation free. What is Beta-lactamases? Meaning of Beta-lactamases medical term. What does Beta-lactamases ... Looking for online definition of Beta-lactamases in the Medical Dictionary? ... beta-lactamase. (redirected from Beta-lactamases). Also found in: Dictionary, Thesaurus, Encyclopedia.. Related to Beta- ... FREQUENCY OF EXTENDED SPECTRUM [beta]-LACTAMASES (ESBLS) AND AMP C [beta]-LACTAMASE PRODUCING ESCHERICHIA COLI AND KLEBSIELLA ...
BLPB stands for Beta-Lactamase-Producing Bacteria. BLPB is defined as Beta-Lactamase-Producing Bacteria rarely. ... Beta-lactamase-producing bacteria can express their pathogenicity directly as a result of their ability to cause infections and ... 2020 https://www.acronymfinder.com/Beta_Lactamase_Producing-Bacteria-(BLPB).html. *Chicago style: Acronym Finder. S.v. "BLPB." ... n.d.) Acronym Finder. (2020). Retrieved November 29 2020 from https://www.acronymfinder.com/Beta_Lactamase_Producing-Bacteria-( ...
This method was validated with ten reference TEM-type extended-spectrum beta-lactamases. The mutations involved in TEM- … ... To rapidly characterise TEM-derived extended-spectrum beta-lactamases a fast and easy method using polymerase chain reaction- ... beta-lactamase conferring low resistance to ceftazidime (TEM-29), was described. TEM-29 derived from TEM-1, with an amino acid ... Molecular characterisation by PCR-restriction fragment length polymorphism of TEM beta-lactamases FEMS Microbiol Lett. 1995 Dec ...
The X-ray structure of Escherichia coli TEM1 beta-lactamase has been refined to a crystallographic R-factor of 16.4% for 22,510 ... Crystal structure of Escherichia coli TEM1 beta-lactamase at 1.8 A resolution Proteins. 1993 Aug;16(4):364-83. doi: 10.1002/ ... The X-ray structure of Escherichia coli TEM1 beta-lactamase has been refined to a crystallographic R-factor of 16.4% for 22,510 ... It was found that the E. coli TEM1 and Staphylococcus aureus PC1 beta-lactamases crystal structures differ in the relative ...
Two chromosome-encoded beta-lactamases have been purified from Citrobacter diversus ULA-27. They exhibited slightly different ... Citrobacter diversus ULA-27 beta-lactamases. Improved purification and general properties.. [G Amicosante, A Oratore, N ...
OXA beta-lactamases (class D). OXA beta-lactamases were long recognized as a less common but also plasmid-mediated beta- ... TEM beta-lactamases (class A). TEM-1 is the most commonly encountered beta-lactamase in gram-negative bacteria. Up to 90% of ... The OXA beta-lactamase family was originally created as a phenotypic rather than a genotypic group for a few beta-lactamases ... Beta-lactamases produced by gram-positive organisms are usually secreted. Beta-lactamase may be clinically beneficial when ...
IPR012338, Beta-lactam/transpept-like. IPR000871, Beta-lactam_class-A. IPR023650, Beta-lactam_class-A_AS. ... IPR012338, Beta-lactam/transpept-like. IPR000871, Beta-lactam_class-A. IPR023650, Beta-lactam_class-A_AS. ... Beta-lactamase SHV-1Add BLAST. 265. Amino acid modifications. Feature key. Position(s). DescriptionActions. Graphical view. ... Beta-lactamase SHV-1 (EC:3.5.2.6*Search proteins in UniProtKB for this EC number. ...
New Delhi Metallo-Beta-Lactamase, or, NDM-1, is the name given to an enzyme discovered in 2009 that is able to be produced ... The majority of the beta-lactamase enzymes are effective on some, or most, of the older antibiotics like cephalosporins and ... New Delhi Metallo-Beta Lactamase (NDM-1) a SuperBug - Information regarding NDM-1 an enzyme that renders bacteria resistant to ... The enzyme belongs to a group of enzymes that are capable of breaking the chemical bonds of a beta-lactam ring, which composes ...
Recombinant Beta-Lactamase Inhibitory Protein (His tag) is an Escherichia coli Full length protein 37 to 201 aa range, , 90% ...
Jacoby GA (2009) AmpC beta-lactamases. Clin Microbiol Rev 22:161-182CrossRefPubMedPubMedCentralGoogle Scholar ... Jiang X, Zhang Z, Li M, Zhou D, Ruan F, Lu Y (2006) Detection of extended-spectrum beta-lactamases in clinical isolates of ... Shahid M, Malik A, Agrawal M, Singhal S (2004) Phenotypic detection of extended-spectrum and AmpC beta-lactamases by a new spot ... Poirel L, Karim A, Mercat A, Le Thomas I, Vahaboglu H, Richard C, Nordmann P (1999a) Extended-spectrum beta-lactamase-producing ...
A beta-lactamase inhibitor is a drug given in conjunction with a beta-lactam antibiotic. Although the inhibitor does not ... Beta-lactamase inhibitors in clinical use include clavulanic acid and its potassium salt (usually combined with amoxicillin or ... "Beta-Lactamase Inhibitors". Department of Nursing of the Fort Hays State University College of Health and Life Sciences. ... Articles on Beta-lactamase inhibitor in N Eng J Med, Lancet, BMJ ... FDA on Beta-lactamase inhibitor CDC on Beta-lactamase inhibitor ...
  • To the Editor: Extended-spectrum [beta]-lactamase (ESBL)-producing organisms have become a common problem for patients in hospitals and other healthcare facilities (1). (thefreelibrary.com)
  • These otics attributed to the production of extended-spectrum putative ESBL- and/or pAmpC-producers constituted the beta-lactamases (ESBLs) and/or plasmid-mediated study sample and were subjected to antimicrobial suscep- AmpC (pAmpC) enzymes [1, 2]. (deepdyve.com)
  • Phenotypic and genotypic characterization of beta- Data on the epidemiology of ESBL- and pAmpC-- lactamases producing Enterobacteriaceae in Africa are still limited. (deepdyve.com)
  • Multidrug resistance bacteria have limited the therapeutic possibilities by producing Extended Spectrum Beta Lactamases (ESBL). (nepjol.info)
  • Community acquired urinary tract infections (CA-UTI) are commonly caused by Escherichia coli and Klebsiella spp which are known extended spectrum beta lactamase (ESBL) producers. (sljol.info)
  • Isolates expressing extended-spectrum beta-lactamase (ESBL) or plasmid-mediated AmpC enzymes are increasingly encountered across the world, in both community- and hospital-onset infections [ 2 ]. (biomedcentral.com)
  • The number of patients infected with extended-spectrum beta-lactamase (ESBL)-producing organisms has increased dramatically worldwide, and high mortality rates are seen in severely ill patients. (elsevier.com)
  • The antibiotic-resistant bacterium Extended Spectrum Beta Lactamase (ESBL) is killing both people and swine in Denmark. (dp.ua)
  • teriaceae resistant to broad-spectrum beta-lactam antibi- Two isolates were recovered from the same sample. (deepdyve.com)
  • Simonsen, G. 2018-05-30 00:00:00 Background: In recent years, the world has seen a surge in Enterobacteriaceae resistant to broad-spectrum beta- lactam antibiotics due to the production of extended-spectrum beta-lactamases (ESBLs) or plasmid-mediated AmpC (pAmpC) enzymes. (deepdyve.com)
  • Extended-spectrum beta-lactamases (ESBLs): Guidance, data, analysis. (tristarparthenonpavilion.com)
  • Available at: https://www.gov.uk/government/collections/extended-spectrum-beta-lactamases-esbls-guidance-data-analysis. (tristarparthenonpavilion.com)
  • Extended Spectrum Beta-Lactamases (ESBLs) encoding genes (TEM, SHV and OXA) were amplified from multidrug resistance E. coli. (scirp.org)
  • 2] CDC (2010) Healthcare Associated Infection: Laboratory Detection of Extended-Spectrum β-Lactamases (ESBLs). (scirp.org)
  • Johnson A , Woodford N , Livermore D M . Laboratory detection of bacteria with extended-spectrum beta-lactamases. (eurosurveillance.org)
  • What are extended-spectrum beta-lactamases? (hstalks.com)
  • The transferable class C beta-lactamases and what we know as extended-spectrum beta-lactamases. (hstalks.com)
  • Community-acquired extended-spectrum [beta]-lactamase producers, United States. (thefreelibrary.com)
  • producing extended-spectrum beta-lactamases. (deepdyve.com)
  • Broad-spectrum beta-lactamase production is associated with increased morbidity and mortality in both high- and low/middle-income countries [9, 10]. (deepdyve.com)
  • Extended-spectrum beta-lactamases: a clinical update. (tristarparthenonpavilion.com)
  • Prevalence, antibiotic sensitivity pattern and genetic analysis of extended spectrum beta la. (sljol.info)
  • There has been a worldwide increase in resistance in these species to antibiotics such as third generation cephalosporins, largely driven by the acquisition of extended-spectrum beta-lactamase or plasmid-mediated AmpC enzymes. (biomedcentral.com)
  • Recent retrospective data suggest that beta-lactam/beta-lactamase inhibitor combinations, such as piperacillin-tazobactam, may be non-inferior to carbapenems for the treatment of bloodstream infection caused by extended-spectrum beta-lactamase-producers, if susceptible in vitro . (biomedcentral.com)
  • 3] Turner, P.J. (2005) Extended-Spectrum Beta-Lactamases. (scirp.org)
  • Bacteria that produce TEM type or SHV type beta lactamases have point mutations in structural genes that have extended the substrate specificity of these beta lactamases. (thermofisher.com)
  • These bacteria may also acquire genes encoding beta-lactamase enzymes that hydrolyse essential beta-lactam antibiotics, rendering such treatment ineffective. (biomedcentral.com)
  • These bacteria are usually multi-resistant, as beta-lactamase genes are frequently co-located with other resistance mechanisms, leaving few treatment options. (biomedcentral.com)
  • Bacterial resistance to beta lactams continues to increase, primarily due to the production of beta lactamases. (thermofisher.com)
  • The beta lactam antibiotics (penicillins and cephalosporins) are the most frequently used antimicrobial agents. (thermofisher.com)
  • Most of the beta-lactamases I'm going to talk about are in Gram-negative bacteria. (hstalks.com)
  • There are, of course, beta-lactamases in Gram-positive bacteria and they have caused problems clinically, but largely they are overcome by new drugs such as methicillin and the newer cephalosporins. (hstalks.com)
  • MA1-20370 detects beta lactamase in bacteria samples. (thermofisher.com)
  • I and my colleagues have spent much of our careers looking at beta-lactamases, both their structure and function, and putting this into context with clinical impact and epidemiology. (hstalks.com)
  • In this presentation I shall talk about the impact of beta-lactamases and outline some of the most important beta-lactamases that we're having to deal with in the clinical situation today. (hstalks.com)
  • Beta lactamases catalyze the hydrolysis of the beta lactam bond, which destroys antibacterial activity. (thermofisher.com)
  • Molecular characterization showed a gene encoding the CTX-M-15 [beta]-1actamase. (thefreelibrary.com)
  • As a result, many of the beta lactamase producing Gram negative pathogens have become multidrug resistant. (thermofisher.com)
  • The following antibody was used in this experiment: beta Lactamase Monoclonal Antibody from Thermo Fisher Scientific, catalog # MA1-20370, RRID AB_2280996. (thermofisher.com)
  • Evaluation of phenotypic tests for the detection of Amp C beta-lactamase in clinical isolates of Escherichia coli. (thefreedictionary.com)
  • Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. (thefreedictionary.com)
  • Transcontinental importation into the UK of Escherichia coli expressing a plasmid-mediated AmpC-type betalactamase exposed during an outbreak of SHV-5 extended-spectrum beta-lactamase in a Leeds hospital. (thefreedictionary.com)
  • Beta-lactam resistance to Escherichia coli was identified prior to the release of penicillin for clinical use, foreshadowing the importance of understanding the role of beta-lactamases-bacterial enzymes that cause resistance to beta-lactam antibiotics-in relation to drug selection. (uspharmacist.com)
  • A 1536-nucleotide-long sequence that carries the ampC beta-lactamase gene of the Escherichia coli K-12 chromosome has been determined. (pnas.org)
  • An Aeromonas hydrophila gene, named cphA, coding for a carbapenem-hydrolyzing metallo-beta-lactamase, was cloned in Escherichia coli by screening an Aeromonas genomic library for clones able to grow on imipenem-containing medium. (asm.org)
  • Eleven isolates including Escherichia coli, Salmonella enteritidis, and Shigella sonnei, obtained in Brazil, Hong Kong, Indonesia, Thailand, and the United States, were found to produce beta-lactamase of the PSE-1 type, which was previously considered to be Pseudomonas specific. (asm.org)
  • Five novel plasmid-determined beta-lactamases named TLE-1, OXA-4, OXA-5, OXA-6, and OXA-7 were detected in ampicillin-resistant isolates of Escherichia coli and carbenicillin-resistant strains of Pseudomonas aeruginosa. (asm.org)
  • Activity of Sulbactum in combination with ceftriaxone in-vitro and in Experimental Endocarditis Caused by Escherichia coli Producing SHV-2-Like B-Lactamase, Antimicrobial Agents and Chemotherapy, Apr. (patentgenius.com)
  • Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical Center. (semanticscholar.org)
  • Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. (semanticscholar.org)
  • Extended-spectrum beta-lactam antibiotics-third generation cephalosporins- are commonly used for treating infections caused by Escherichia coli in Kathmandu Medical College and Teaching Hospital (KMCTH), Nepal. (biomedcentral.com)
  • During January--June 2010, three Enterobacteriaceae isolates carrying a newly described resistance mechanism, the New Delhi metallo-beta-lactamase (NDM-1) ( 1 ), were identified from three U.S. states at the CDC antimicrobial susceptibility laboratory. (cdc.gov)
  • This is the first report of NDM-1 in the United States, and the first report of metallo-beta-lactamase carriage among Enterobacteriaceae in the United States. (cdc.gov)
  • Molecular characterization of extended-spectrum beta-lactamase producing Enterobacteriaceae in a Saudi Arabian tertiary hospital. (thefreedictionary.com)
  • Barwa R, Abdelmegeed E, Abd El Galil K (2012) Occurrence and detection of AmpC-lactamases among some clinical isolates of Enterobacteriaceae obtained from Mansoura University Hospitals, Egypt. (springer.com)
  • MIC breakpoints were lowered for many beta-lactam antibiotics, including extended-spectrum cephalosporins, to improve the detection of known resistance in Enterobacteriaceae. (uspharmacist.com)
  • To determine the frequency of intestinal colonization with extended-spectrum b-lactamase-producing Enterobacteriaceae in newborns. (unboundmedicine.com)
  • 63/102 (61.7%) were colonized by extended-spectrum b-lactamase-producing Enterobacteriaceae on day 7, 17/21 (81%) on day 14, and 6/8 (75%) on day 21 of hospitalization. (unboundmedicine.com)
  • A predominant clone (95%) was found in hospital B, and a major clone (75%) in Hospital A. Other extended-spectrum b-lactamase-producing Enterobacteriaceae isolates were Enterobacter spp. (unboundmedicine.com)
  • High rates of colonization and horizontal transmission of extended-spectrum b-lactamase-producing Enterobacteriaceae were found in the newborn care units of two general hospitals. (unboundmedicine.com)
  • Beta-Lactamases in Enterobacteriaceae : an Ever-Pr. (who.int)
  • Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. (springer.com)
  • Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. (asm.org)
  • We recently published the first known report of a Verona integrin-encoded metallo-beta-lactamase-1 (VIM-1) in a member of the Enterobacteriaceae (in this case Klebsiella pneumoniae , KPSA01) outside Europe. (scielo.org.za)
  • Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. (semanticscholar.org)
  • A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. (semanticscholar.org)
  • The Continuing Plague of Extended-spectrum β-lactamase-producing Enterobacteriaceae Infections. (semanticscholar.org)
  • Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting. (semanticscholar.org)
  • Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). (semanticscholar.org)
  • Simonsen, G. 2018-05-30 00:00:00 Background: In recent years, the world has seen a surge in Enterobacteriaceae resistant to broad-spectrum beta- lactam antibiotics due to the production of extended-spectrum beta-lactamases (ESBLs) or plasmid-mediated AmpC (pAmpC) enzymes. (deepdyve.com)
  • The isolates resistant to ceftazidime, cefotaxime and cefoxitin were screened positive for AmpC beta-lactamases and further confirmed by inhibitor based method using boronic acid disc. (thefreedictionary.com)
  • The ampC beta-lactamase with a substrate specificity for cephalosporins showed no significant sequence homologies with beta-lactamases of the penicillinase type or with D-alanine carboxypeptidases. (pnas.org)
  • However, because the region around serine-80 of the ampC beta-lactamase has extensive homology with an active-site fragment of the Pseudomonas aeruginosa cephalosporinase, we suggest that the ampC cephalosporinase as well as related cephalosporinases form a distinct group of serine beta-lactamases that have an evolutionary origin different from that of the serine penicillinases and thus constitute a new class of beta-lactamases. (pnas.org)
  • Plasmid-mediated AmpC beta-lactamases have arisen through the transfer of chromosomal genes for the inducible AmpC beta-lactamase onto plasmids. (cdc.gov)
  • This transfer has resulted in plasmid-mediated AmpC beta-lactamases in isolates of E. coli, Klebsiella pneumoniae, Salmonella spp. (cdc.gov)
  • To date, all plasmid-mediated AmpC beta-lactamases have similar substrate profiles to the parental enzymes from which they appear to be derived. (cdc.gov)
  • AmpC, also known as Beta-lactamase, is the most widespread resistance mechanism to beta-lactam antibiotics, such as the penicillins and the cephalosporins. (acris-antibodies.com)
  • To avoid development of resistance, beta-lactamase inhibitors are administered with the beta-lactam antibiotics so the action of beta-lactamase is inhibited. (drugs.com)
  • Beta-lactamase inhibitors in clinical use include clavulanic acid and its potassium salt (usually combined with amoxicillin or ticarcillin ), sulbactam and tazobactam . (wikidoc.org)
  • Inhibitors of .beta. (patentgenius.com)
  • Rahil, J. and Pratt, RF, "Characterization of Covalently Bound Enzyme Inhibitors as Transition-State Analogs by Protein Stability Measurements: Phosphate Monoester Inhibitors of a .beta. (patentgenius.com)
  • Beta Lactamase Inhibitors in Research: Anti-Seizure 2016-10-24 16:00:22 Beta-lactam antibiotics contain a cyclic amide ring of which mimics the structure of the terminal amino acid residues comprising the peptidoglycan matrix. (agscientific.com)
  • Disclosed are small molecule inhibitors of .alpha.v.beta.6 integrin, and methods of using them to treat a number of diseases and conditions. (patents.com)
  • Cui-Gai Bai, Yin-Tong Xu, Ning-Ning Li, Jing-Han Wang, Cheng Yang, Yue Chen and Hong-Gang Zhou, "Cysteine and Its Derivatives as New Delhi Metallo-beta-lactamase-1 Inhibitors", Current Enzyme Inhibition (2015) 11: 46. (eurekaselect.com)
  • In Vitro Activity of Beta-Lactam Agents and Beta-Lactamase Inhibitors in Clinical Isolates of Acinetobacter baumannii, Revista Espanola de Quimioterapia, Jun. (patentgenius.com)
  • The beta-lactamase-inhibitor protein (BLIP) is produced by Streptomyces species. (ebi.ac.uk)
  • Crystal structure and kinetic analysis of beta-lactamase inhibitor protein-II in complex with TEM-1 beta-lactamase. (ebi.ac.uk)
  • We also studied the inactivation of the R164H and R164S mutants with tazobactam and SA2-13, a unique β-lactamase inhibitor that undergoes a distinctive reaction chemistry in the active site. (rcsb.org)
  • A beta-lactamase inhibitor is a drug given in conjunction with a beta-lactam antibiotic . (wikidoc.org)
  • Although the inhibitor does not usually have significant antibiotic activity on its own, [1] it still plays an important role by disabling or slowing down the action of beta-lactamase . (wikidoc.org)
  • WALTHAM, Mass.--( BUSINESS WIRE )-- Entasis Therapeutics , a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced initiation of a Phase 1 clinical trial of its novel oral beta-lactamase inhibitor ETX0282. (businesswire.com)
  • The invention describes a composition for combating beta-lactamase-mediated antibiotic resistance using beta-lactamase inhibitor useful for injection, capable of pharmaceutical application. (patentgenius.com)
  • Structure-Activity Studies of the Inhibition of Serine .beta. (patentgenius.com)
  • The Synthesis and Serine .beta. (patentgenius.com)
  • Rahil, J. and Pratt, RF, "Structure-Activity Relationships in the Inhibition of Serine .beta. (patentgenius.com)
  • Carbapenemases (β-lactamases able to inactivate carbapenems) have been identified in both serine β-lactamase (SBL) and metallo-β-lactamase (MBL) families. (uio.no)
  • β-lactamase II is cephalosporinase. (thefreedictionary.com)
  • Crystallographic Structure of a Phosphonate Derivative of the Enterobacter cloacae P99 Cephalosporinase: Mechanistic Interpretation of a .beta. (patentgenius.com)
  • particularly if the person is infected with a gram-negative bacterial type and is receiving treatment with an antibiotic that contains a beta-lactam ring structure. (disabled-world.com)
  • Bacterial resistance to beta lactams continues to increase, primarily due to the production of beta lactamases. (thermofisher.com)
  • Beta-lactamases are important mediators of bacterial resistance to beta-lactam agents. (asmscience.org)
  • beta-Lactamases: protein evolution in real time. (nih.gov)
  • These data were in agreement with the molecular mass of the original Aeromonas enzyme and of the recombinant enzyme produced in E. coli, evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of crude beta-lactamase preparations followed by renaturation treatment for proteins separated in the gel and localization of protein bands showing carbapenem-hydrolyzing beta-lactamase activity by a modified iodometric technique. (asm.org)
  • Beta-lactamase inhibitory protein antibody LS-C681992 is a biotin-conjugated rabbit polyclonal antibody to streptomyces clavuligerus Beta-lactamase inhibitory protein. (lsbio.com)
  • Molecular characterization showed a gene encoding the CTX-M-15 [beta]-1actamase. (thefreelibrary.com)
  • Beta-lactamase gene bla or ampR is used in molecular cloning as a selection marker, since cells bearing plasmids encoding the gene are resistant to ampicillin and carbenicillin . (openwetware.org)
  • Staphylococcus aureus produces four types of beta-lactamase (A, B, C, and D). To investigate the effect of specific beta-lactamase type upon staphylococcal resistance, each beta-lactamase was purified to homogeneity, and the Michaelis constants (Km values) and turnover numbers (kcat values) for various penicillin and cephalosporin substrates were determined. (asm.org)
  • In contrast to earlier reports suggesting that the type B beta-lactamase is relatively inefficient in hydrolyzing penicillin G, we found only minor differences in the specific activities and kcat values of the type A, B, and C beta-lactamases. (asm.org)
  • The type D beta-lactamase was distinctly less active against penicillin G, however, exhibiting only 15 to 25% of the kcat values of the other beta-lactamases. (asm.org)
  • The disc diffusion test with penicillin G and the cloverleaf method could not separate beta-lactamase-positive from beta-lactamase-negative strains. (lu.se)
  • Beta-Lactamase can be used to reduce levels of penicillin in patients with severe penicillin reactions. (agscientific.com)
  • Penicillinase is a specific type of β lactamase, showing specificity for penicillins , again by hydrolysing the beta-lactam ring. (wikidoc.org)
  • The ability of an organism to produce a β-lactamase may be chromosomal and constitutive or a plasmid-associated acquired property. (thefreedictionary.com)
  • The organism was resistant to beta-lactams and after the organism's genetic and antibiotic resistance mechanisms were studied - NDM-1 and its genetic source were discovered. (disabled-world.com)
  • This review considers the ability of the prevalent beta-lactamases to cause resistance to widely used beta-lactams, whether resistance is accurately reflected in routine tests, and the extent to which the antibiogram for an organism can be used to predict the type of beta-lactamase that it produces. (asm.org)
  • Plasmids of IncH2 and IncFIme were shown to contain 8 x 10(6)-molecular-weight transposons Tn1401 and Tn1402 that encoded PSE-1 beta-lactamase production, resistance to streptomycin and spectinomycin via AAD(3"), and resistance to sulfonamide. (asm.org)
  • To investigate the risk factors, clinical features, molecular epidemiology, and treatment outcomes associated with an outbreak of infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis . (annals.org)
  • The two tandemly repeated domains of BLIP have an alpha(2)-beta(4) structure, the beta-hairpin loop from domain 1 inserting into the active site of beta-lactamase [ PMID: 8605632 ]. (ebi.ac.uk)
  • I and my colleagues have spent much of our careers looking at beta-lactamases, both their structure and function, and putting this into context with clinical impact and epidemiology. (hstalks.com)
  • Lactamase Inhibitory Activity of Some Phosphonamidate Analogues of Dipeptides," Bioorganic & Medi. (patentgenius.com)
  • Agarwal, J., Kalyan, R. and Singh, M. (2009) High-Level Aminoglycoside Resistance and Beta-Lactamase Production in Enterococci at a Tertiary Care Hospital in India. (scirp.org)
  • Low amoxicillin concentrations can be caused by beta-lactamase activity in the lungs. (dovepress.com)
  • MIC 90 had higher beta-lactamase activity in sputum than patients with a concentration ≥MIC 90 . (dovepress.com)
  • Sputum and serum samples were collected at day 3 of treatment to determine beta-lactamase activity in sputum and amoxicillin concentrations in both sputum and serum. (dovepress.com)
  • For the rapid chromogenic detection of beta-lactamase activity. (openwetware.org)
  • Described herein are compounds and compositions that modulate the activity of beta-lactamases. (patents.com)
  • The lactamase enzyme breaks that ring open, deactivating the molecule's antibacterial properties. (wikidoc.org)